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I .  I N T R O D U C T I O N
Type 1 diabetes mellitus (T1DM) is characterized by absolute insulin-deficiency, resulting 
from immune-mediated destruction of insulin-producing β-cells of the pancreas.(1) Insulin 
replacement and frequent monitoring of blood glucose by patients themselves (SMBG) are the 
hallmarks of optimal treatment of T1DM.(2)
Despite advances in insulin therapy during the past 25 years, relatively few patients with 
T1DM are able to reach the glycemic and HbA
1c 
target levels, obtained by normal metabolic 
control in non-diabetic subjects(3), and they generally have relatively large intra-individual 
variations in blood glucose levels. Although insulin analogues and insulin pumps enable a level of 
insulin replacement that approaches the finesses of normal physiological control, it still remains 
impossible to achieve fully normal glucose physiology. This inability might be related to normal 
intra-individual variations in physiological factors, which may interfere with glucoregulation in 
healthy subjects and also in patients with T1DM, e.g. food intake, physical activity, and stress.(4-7)
Voluntary sleep curtailment is common in our modern 24-h society. Increasing evidence 
exists for an important role of sleep as another physiological determinant of glucose metabolism 
in healthy people.(8-13) Because altered sleep characteristics are known to affect glucoregulation 
in healthy controls, we hypothesized that this may also hold true for patients with T1DM. 
In this concept, altered sleep characteristics may be another factor challenging optimal 
glucoregulation in these patients. The effects of impaired sleep as a physiological determinant of 
impaired glucose regulation in patients with T1DM had not been studied previous to the studies 
documented in this thesis. Although there is only limited evidence that T1DM is associated with 
altered sleep patterns and sleep disorders(14-18), metabolic dysregulation, frequently found in 
patients with T1DM, could still impair sleep characteristics; in turn, disturbed sleep could impair 
glucose metabolism, creating a vicious circle. 
The studies described in this thesis focus on the interaction between sleep and glucose 
regulation in adult patients with T1DM. We studied effects of both shortened sleep duration 
and altered sleep composition on insulin sensitivity in adult patients with T1DM and healthy 
controls. In addition, we evaluated sleep patterns in T1DM, and studied the effect of 
hyperglycemia, induced by reduced insulin therapy, on sleep characteristics in patients with 
T1DM. Since T1DM was associated with cognitive impairment(19;20), we also studied the effect of 
sleep characteristics on sustained attention in T1DM. 
I I .  T Y P E  1  D I A B E T E S  M E L L I T U S  ( T 1 D M )
1 .  E p i d e m i o l o g y
T1DM accounts for 5-10% of all cases of diabetes. Although it most commonly presents in patients 
younger than 16-18 years of age(3) it may develop at any age.(21) There is an enormous geographical 
variation in incidence of DM1 around the world, ranging from fewer than 4 cases per 100.000 
children and adolescents(younger than 18 years) in much of Africa and Asia to more than 20 
per 100.000 in Canada, Australia, and parts of Europe, with the highest reported incidences 
in Finland and Sardinia (about 50 and 37-45 cases per 100.000 children younger than 15 years, 
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respectively.(22-26) The incidence of T1DM increases rapidly by 2% to 5% per year worldwide, 
especially in the youngest age group of who are less than 5 years of age.(27) If these trends continue, 
a doubling of new cases of T1DM in European children younger than 5 years is predicted to occur 
between 2005 and 2020. Likewise the number of cases younger than 15 years will rise by 70%.(28) 
There is no overall gender difference in the incidence of childhood DM1, but in select populations 
(e.g., older Europeans), there seems to be an increased risk for males (3:2 male to female ratio).(29) 
2 .  P a t h o g e n e s i s
In the early 1980s Eisenbarth first describes the main phases of the pathogenesis of the immune 
form of T1DM.(30) Available evidence suggests a strong genetic component, the most important 
of which relates to the HLA class II locus on chromosome 6, and with lesser contribution from 
other non-HLA genes, including the insulin gene on chromosome 11(31;32), and the cytotoxic T 
lymphocyte antigen 4 (CTLA4) on chromosome 2q33.(33) Genes located within the HLA class 
II region on chromosome 6p21 are considered to be the major susceptibility genes for T1DM 
and account for approximately 50% of the genetic susceptibility.(34-37) Both susceptibility, 
associated with diabetes resistance, and protective HLA haplotypes, associated with protection 
from the disease, are identified.(36) The HLA haplotypes, DR4-DQ8 and DR3-DQ2, contribute 
to the greatest risk and are present in more than 90% of the children with T1DM. About 
30% of patients with T1DM have both haplotypes, which combination confers the greatest 
susceptibility.(38) These HLA susceptibility genes are thought to be important regulators 
of the immune response and have a major role in presentation of antigens involved in the 
pathogenesis of T1DM to antigen receptors on T-cells, the main effector cells of the destructive 
autoimmune process. The abnormal activation of the T-cell-mediated immune system by one 
or more environmental triggers in susceptible individuals leads to an inflammatory response 
in the islets of Langerhans, as well as to an humoral response with production of antibodies 
to β-cells antigens.(3) Several autoantibodies have been identified that may play an important 
role in initiation or progression of auto-immune islet injury(39), including antibodies to insulin 
(IAA)(40), glutamic acid decarboxylase (GAD-65)(41), protein tyrosine phosphatase IA2 (IA-2AA)(42), 
and zinc transporter (ZnT8).(43) The presence and persistence of these autoantibodies facilitates 
the likelihood of progression to clinical disease(44;45), but there is no evidence that any of these 
antibodies have an active role in the pathogenesis of T1DM. The lifelong risk of DM1 is markedly 
increased in close relatives of patients with T1DM, averaging about 6 percent in their offspring, 
5% in siblings, and 50% in identical twins (versus 0.4% in subjects with no family history).(46-48) 
Environmental factors that trigger the onset of clinical disease are not well understood, but 
an interaction between genetic susceptibility and environmental factors is thought to be the 
fundamental element for the disease. Putative triggers include viruses (e.g., enteroviruses, 
coxsackie B, congenital rubella)(49), environmental toxins (e.g. , nitrosamines)(50;51), or foods 
(e.g., early exposure to cow’s milk proteins, cereals, or gluten).(52-57) Several pregnancy related 
and perinatal factors were associated with a small increase in risk of T1DM.(58) There is evidence 
for a protective role of omega-3 fatty acids(59) and vitamin D supplements(60) in the inflammatory 
response associated with autoimmune islet cell destruction. 
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3 .  D i a g n o s i s 
The symptoms of T1DM are caused by hyperglycemia and include polydipsia, meaning excessive 
drinking, polyuria, or excessive urination, and considerable weight loss. Other symptoms may 
include lethargy, polyphagia, frequent yeast infections and urinary tract infections, blurred 
vision, impotence, nausea, vomiting, and dehydration. Diagnostic criteria for diabetes described 
the WHO and American Diabetes Association (ADA) are a fasting plasma glucose >7.0 mmol/L, 
or a 2-hour glucose >11.1 mmol/L during a 75 gram oral glucose tolerance test (OGTT), confirmed 
by repeat testing on a different day in the absence of unequivocal hyperglycemia, or when 
classical symptoms of hyperglycemia are present and a random plasma glucose level is >11.1 
mmol/L.(2) The presence of T1DM is suggested by presence of serum auto-antibodies to glutamic 
acid decarboxylase (GAD-65), protein tyrosine phosphatase IA2 (IA-2AA) and/or insulin (IAA).(39) 
4.  C o m p l i c a t i o n s 
The quality of long term glycemic control, as reflected in HbA
1c
 values, is associated with the onset 
and progression of the complications of T1DM.(61-64) Long-term diabetes-related complications are 
divided into microvascular disease – i.e. nephropathy, retinopathy, and peripheral neuropathy-, 
and macrovascular disease – i.e. cardiovascular, cerebrovascular, and peripheral vascular 
disease-, which account for most of the increased morbidity and mortality associated with the 
disease.(3) Risk factors for diabetes-related complications include poor glycemic control, early 
onset and long duration of T1DM, genetic susceptibility, gender, hypertension, hyperlipidemia, 
and lifestyle factors (e.g., smoking, obesity, exercise).(3) The mechanism by which poor glycemic 
control predisposes to vascular disease is not completely understood. Putative mechanisms, 
associated with hyperglycemia, include: 1) accumulation of advanced glycosylation end products 
that contribute to microvascular disease, 2) accumulation of sorbitol, which interferes with 
cellular metabolism, 3) end-organ response with activation of cytokines, profibrotic elements, 
vascular growth factors, inflammation and activation of protein kinase C. Genetic susceptibility 
is another important factor for the development of complications.(62;65)
5.  M a n a g e m e n t
Insulin therapy and frequent monitoring of blood glucose by patients themselves is fundamental 
to account for deficient endogenous insulin secretion and to attain normoglycemia.(2) Long-term 
glycemic control is best measured by HbA
1c
 concentrations, which reflects the average glycemic 
concentration during the previous three months.(66) Most patients use basal-bolus approaches 
to insulin delivery with either multiple daily insulin injections (MDII) or continuous subcutaneous 
insulin pumps (CSII).(67;68) There is a small but clinically significant improvement in HbA
1c
 levels 
with use of CSII compared to MDII.(69;70) Despite advances in insulin therapy during the past 
25 years, only a few individuals with T1DM are able to reach glycemic and HbA
1c 
target levels 
consistently, reflected in large intra-individual variations in blood glucose.(3) Intervention 
studies on the effect of short treatment with CSII therapy showed some improvement of 
insulin resistance after CSII in patients with T1DM, but their insulin sensitivity remained lower 
than that of healthy subjects.(71-74) Other components of management of patients with T1DM 
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include nutritional planning and carbohydrate counting(75-77), screening for and treatment of 
diabetes-related complications, screening for and treatment of diabetes –associated disorders, 
attention to psychological and psychosocial well-being, and avoidance or treatment of severe 
hypoglycemia and diabetic ketoacidosis.(3) There is an inverse relation between glycemic control 
and the risk of hypoglycemic episodes. Repeated episodes of severe hypoglycemia are a risk 
factor for cognitive impairment in patients with T1DM.(78;79)
I I I .  S L E E P
1 .  D e f i n i t i o n
Sleep is a natural and reversible periodic state, characterized by reduced or absent awareness 
and attention, limited sensory activity and inactivity of nearly all striated muscles. The 
reversible nature and predictable cycling of sleep stadia are features that distinguish sleep from 
pathological unconsciousness.(80)
2 .  S l e e p  a r c h i t e c t u r e  a n d  s t a d i a
Normal sleep is composed of rapid eye movement (REM) sleep and non-rapid eye movement 
(NREM) sleep, with NREM being subdivided into 3 stages representing a continuum of 
relative depth: stage N1, N2, and N3 with stage N3 designated as deep sleep or ‘slow-wave 
sleep’ (SWS).(81) Each sleep stage has unique characteristics, including brain wave patterns on 
electroencephalography (EEG), eye movements and muscle tone. NREM and REM sleep stages 
alternate cyclically and display an ultradian rhythm, with a 90-120 minute cycle. Ultradian rhythms 
are recurrent periods or cycles repeated throughout a 24-hour circadian day. The cycle repeats 
4-5 times throughout a normal 8-hour sleep period. Sleep begins in NREM and progresses 
through deeper NREM stages before the first episode of REM sleep begins approximately 
90 minutes later. Although this cycle repeats through the night, the duration of REM sleep 
increases and the duration and depth of SWS decreases with each cycle. As a consequence of 
these shifts in duration, SWS predominates in the first third of the night and REM-sleep in the 
last third.(82;83) Most of the entire sleep time (75-85%) is spent in NREM-sleep. About 1-5% of 
nocturnal sleep is accounted for by short normal periods of wakefulness.(80) Polysomnography 
describes the recording of various signals including the EEG, electro-oculography (EOG), and 
electromyography (EMG) used to distinguish between different sleep stages as well as to record 
additional signals such as respiratory or circulatory ones to diagnose sleep disorders.(80;81)
N R E M  s l e e p 
NREM sleep is defined as ‘a relatively inactive yet actively regulating brain in a movable body’.(82) 
During NREM sleep, cognitive activity is typically fragmented, and body activity periodically 
occurs as a person moves through the three stages of the NREM sleep. The three NREM stages 
roughly parallel a depth of sleep continuum with arousal thresholds generally lowest in N1 and 
highest in N3. Stage N1, drowsiness, is the transition from wakefulness to sleep and the lightest 
stage of sleep. It is characterized by relatively fast EEG frequencies with low amplitude. During 
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N1, muscle tone starts to decrease and attention and awareness of the external environment 
diminish. This stage accounts for 2 to 5 percent of the total sleep time (TST) in young adults. An 
increased proportion of stage N1 suggests sleep fragmentation due to a sleep disorder. Stage 
N2 is called ‘intermediate’ sleep and is characterized by a slowing of the main EEG frequency, 
the appearance of typical EEG phenomena such as sleep spindles and K-complexes, a further 
decrease in muscular activity, and loss of awareness of the external environment. Stage N2 sleep 
typically accounts for 40-50 percent of the total sleep time (TST). Benzodiazepines increase N2 
sleep time at the expense of stage N3. The final NREM stage, N3 or SWS, is characterized by low 
frequency high-amplitude delta EEG waves, and accounts for 20 percent of the TST.
R E M  s l e e p 
REM sleep is defined as a ‘highly activated brain in a paralyzed body’.(82) It makes up about 20-25 
percent of the total sleep time (TST) and is characterized by: 1) episodic bursts of rapid eye 
movements; 2) a low-voltage relatively fast EEG that resembles an active, awake pattern; 3) atonia 
of most skeletal muscles, excepting some such those involved in respiration; and 4) bursts of 
autonomic activity. REM sleep can be divided as having tonic and phasic periods, distinguished by 
short clusters of REM activity (phasic) that are followed by periods of relative inactivity (tonic).(80)
3 .  D e t e r m i n a n t s  o f  s l e e p 
Sleep is thought to be regulated by several processes. The ultradian rhythm controls the 
NREM-REM cycle, whereas homeostatic drive (e.g. increased sleepiness follows longer 
periods of wakefulness) and circadian sleep-wake rhythms determine the amount and timing 
of sleep.(80;82) Age, prior sleep history and the sleep environment, circadian rhythm disorders, 
external temperature, drugs, medical, neuropsychiatric, sleep and behavioral disorders are 
important factors which affect both sleep duration and stage distribution.(82;84-86)
4.  T h e  f u n c t i o n  o f  s l e e p 
Several theories have been proposed to describe the function of sleep, but the ‘restorative 
theory of sleep’ is most accepted. SWS is thought to be the most ‘restorative’ of all sleep stages.(87) 
Several important physiological activities occur during SWS, including reductions in heart rate, 
blood pressure, sympathetic nervous activity, while vagal tone increases.(88) SWS is also associated 
with a decrease in brain glucose metabolism.(89) Additionally, hormone release is modulated by 
SWS. The release of the hypothalamic-pituitary-adrenal (HPA) system is inhibited(90), whereas 
growth hormone (GH) and prolactin secretion are increased. The counterregulatory hormones 
GH and cortisol have both important roles in glucose metabolism and their levels are influenced 
by impaired sleep.(91) Studies evaluating the effect of sleep deprivation indicated impairments 
in cognitive and physical performance(92;93), and chronic sleep deprivation is associated with 
numerous cardiometabolic disturbances, including obesity, hypertension, dysfunction of 
glucose metabolism, increased diabetes risk, and even mortality.(94;95) 
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I V .  S L E E P  A N D  G L U C O S E R E G U L A T I O N
1 .  E f f e c t  o f  s l e e p  c h a r a c t e r i s t i c s  o n  g l u c o s e  r e g u l a t i o n 
In physiological conditions glucose metabolism shows a circadian rhythm with intra-
individual daytime and nighttime variations in glucose tolerance.(91;96;97) Various mechanisms 
operate during nocturnal sleep to maintain stable glucose levels during the night.(91) In 
addition to circadian rhythmicity, sleep plays an important role in the regulation of glucose 
regulation during the night.(97;98) During the first half of the sleep period glucose tolerance 
markedly decreases by diminished glucose utilization because of the predominance of 
SWS. The initiation of SWS is temporally associated with transient metabolic, hormonal, and 
neurophysiological changes, all of which could affect glucose metabolism, including a 30-40% 
decrease in cerebral glucose uptake, suppression of corticotropic and sympathetic activity, 
rapid anti-insulin-like effect by an increased growth hormone (GH) release, and decreased 
muscle tone.(11;99) During the latter part of the sleep, plasma glucose levels progressively 
decrease towards pre-sleep values, reflecting increased glucose utilization due to the increase 
in awakenings and REM stages.(98-101)
a .  S l e e p  d u r a t i o n 
Voluntary sleep curtailment has become a common behavior pattern in our modern ‘24-hour’ 
society. There is strong evidence that partial sleep restriction affects glucose regulation. A 
pioneering study by Van Cauter and colleagues(10) showed a 40% reduction in glucose tolerance, 
measured with the intravenous glucose tolerance test (ivGTT), and other endocrine and 
metabolic changes associated with diabetes, after six consecutive nights of only four hours sleep 
per night in 11 healthy young men. Other experimental(102) and epidemiological(8;9;13;94;103;104) studies 
confirmed a strong association between (partial) sleep restriction during multiple nights and 
glucose tolerance in healthy subjects. Subsequent nights with partial sleep restriction result in 
impaired glucose tolerance in healthy controls, but the effect of one single night of partial sleep 
deprivation on insulin sensitivity had not been characterized in healthy controls. Moreover, 
previous studies did not include the assessment of insulin sensitivity by the hyperinsulinemic 
euglycemic clamp method, which is considered to be the gold standard for measurement of 
insulin sensitivity.(105) We therefore evaluated the effect of a single night of partial sleep restriction 
on parameters of insulin sensitivity, assessed by the hyperinsulinemic euglycemic clamp studies 
combined with tracer dilution of [6,6-2 H
2
] glucose in healthy controls (Chapter 2). 
As said, glucose regulation cannot be normalized despite intensive insulin therapy in most 
patients with T1DM, apparent as large intra-individual variations in plasma glucose levels.(3) 
Subtle intra-individual variations in glucoregulation and insulin sensitivity depend on variations 
in several physiological determinants, such as dietary factors, exercise and psychosocial 
factors.(4-7) Since multiple nights of impaired sleep are known to impair glucose metabolism in 
healthy controls, we hypothesized that impaired sleep characteristics in patients with T1DM 
could contribute to the intra-individual variations in glucose regulation, and could be another 
physiological determinant of impaired glucose regulation seen in these patients. Therefore, we 
compared the effects of one single night of reduced sleep duration with those of a night of normal 
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sleep duration on hepatic and peripheral insulin sensitivity, as assessed by the hyperinsulinemic 
euglycemic clamp with stable isotopes, in adult patients with T1DM (Chapter 3). 
b .  S l e e p  c o m p o s i t i o n
In addition to sleep duration, the composition of sleep in terms of sleep stages is also a 
determinant of glucose metabolism in healthy controls. Research has supported the clear 
role of SWS in the maintenance of normal glucose metabolism.(11;91;96;98) Tasali and colleagues(11) 
showed a markedly decreased insulin sensitivity and glucose tolerance measured with the 
ivGTT in young healthy controls after selective suppression of SWS, without a change in TST, 
during three consecutive nights. Selective SWS suppression was reached by delivering acoustic 
stimuli on varying frequency and intensity to speakers placed on each side on the bed of the 
subjects. However, the effects of one single night of controlled SWS suppression on insulin 
sensitivity, measured by the hyperinsulinemic euglycemic clamp method, have not been 
studied in healthy subjects before. Therefore, in Chapter 4, we compared the effects of one 
single night of impaired sleep quality – by selective SWS suppression - with those of a night of 
normal sleep on hepatic and peripheral insulin sensitivity, using a hyperinsulinemic euglycemic 
clamp with stable isotopes ([6,6-2 H
2
] glucose), in healthy controls. We hypothesized that 
selective suppression of SWS would decrease insulin sensitivity in healthy controls, which in 
turn may contribute to the intra-individual variations in plasma glucose in patients with T1DM. 
2 .  S l e e p  c h a r a c t e r i s t i c s  i n  p a t i e n t s  w i t h  T 1 D M
The interaction between T1DM and sleep characteristics has not been extensively studied. 
Jauch-Chara and colleagues reported altered sleep architecture in 14 non-hypoglycemic adult 
patients compared with healthy controls. The patients spent more time in lighter sleep stages 
and less time in SWS.(16;106) The authors suggested that T1DM was associated with disruption 
of the sleep-wake cycle. A pilot study of Borel and colleagues(14) showed a high prevalence 
of obstructive sleep apnea (OSA) in 37 non-obese adults with T1DM. Available evidence 
showed that children with T1DM have a more disrupted sleep with more frequent and longer 
awakenings, and more sleep disorders, such as more frequent and longer lasting apneas and 
restless legs syndrome, than healthy children.(15;17;18) These studies(15-18) investigated relatively few 
subjects or children with T1DM. The relation between sleep characteristics and glucoregulation 
has not been studied in adult patients with T1DM. Therefore, in Chapter 5 we compared 
subjective sleep characteristics measured by validated sleep questionnaires, between a large 
cohort of adult patients with T1DM with individually age, gender and BMI matched healthy 
controls. In addition, we related these sleep characteristics to the quality of glycemic control, 
i.e. HbA
1c
 values, and assessed other possible risk factors for impaired sleep characteristics 
in adult patients with T1DM. Our primary hypothesis was that adult patients with T1DM have 
alterations in subjective sleep characteristics compared with individually matched healthy 
controls. In addition, we hypothesized that subjective sleep disturbances would be associated 
with impaired glucoregulation. If T1DM indeed causes disruptions of sleep patterns, this may in 
turn impair glucose regulation, creating a vicious circle. 
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3.  C o n s e q u e n c e s  o f  i m p a i r e d  g l u c o s e  r e g u l a t i o n  o n  s l e e p  c h a ra c t e r i s t i c s
Various aspects of diabetes may be linked to disturbed sleep, including physical complications 
of the disease, metabolic fluctuations, psychological factors, and high prevalence of sleep 
disorders.(106;107) A study of Perfect et al(106) showed an association between higher HbA
1c
 and 
reduced SWS in diabetic children with T1DM. We hypothesized that metabolic dysregulation 
induced by reduction in insulin therapy in patients with T1DM may affect sleep characteristics. 
If so, this may induce a vicious circle: metabolic dysregulation would impair sleep and that in 
turn results in impaired glucose tolerance and insulin resistance. Therefore, we evaluated in 
Chapter 6 the effects of controlled hyperglycemia on sleep characteristics in well-controlled 
(HbA
1c 
below 8% during the year prior to the start of the study) adult patients with T1DM on stable 
continuous subcutaneous insulin infusion (CSII). In order to obtain and maintain hyperglycemia 
during the night with glucose levels ~15 mmol/L, the basal and bolus insulin infusions of the 
patients with T1DM were reduced by 50%, compared with the euglycemic occasion.
V .  S L E E P  A N D  C O G N I T I O N
Patients with T1DM perform less well on neuropsychological tests including intelligence, 
psychomotor speed, visual and sustained attention, cognitive flexibility, visual perception, and 
speed of information processing.(19;20) Although various disease-related variables are associated with 
cognitive impairment – e.g. chronic hyperglycemia(108), microangiopathy(109;110), age at onset(109;111), 
disease duration(111), and structural brain defects(112;113)– the pathophysiology of cognitive dysfunction 
in T1DM is not well understood. Studies on the effect of severe hypoglycemia on cognitive function 
reported conflicting results. Whereas some retrospective studies suggested an association in adult 
patients(114;115), large prospective studies failed to conform this.(116;117) Disturbed sleep might well be 
another determinant of impaired cognitive function in patients with T1DM. Disturbed sleep impairs 
daytime functioning, one expression of which is a decline in sustained attention, measurable as 
prolongation of reaction time (RT), i.e. speed, and an increased number of errors, i.e. accuracy.(118) 
Decreased sleep duration was associated with decreased speed and the beginning of accuracy 
failure in healthy controls.(118;119) Hence, disturbed sleep characteristics might contribute to cognitive 
problems in T1DM. Deficits in sustained attention have already in part been reported in previous 
studies of patients with T1DM.(120-122) Those studies investigated sustained attention in children(121), in 
a controlled setting to investigate the effect of acute hypo- or hyperglycemia(120), or used tests like 
the digit vigilance test(122), the lottery ticket test(120) or the elevator counting test.(121) The Sustained 
Attention to Response Task (SART)(123) that assesses sustained attention, has been shown to be 
sensitive to sleep deprivation in healthy controls(124) and to reflect excessive sleepiness in sleep-
disordered patients.(125) Sustained attention and its relation with sleep characteristics, have, however, 
not been studied in adult patients with T1DM. The SART takes a short time to perform, and is easy 
to administer, which make the test useful in a clinical setting. Therefore, we examined sustained 
attention – i.e. RT and number of omission and commission errors – in adult patients with T1DM, 
compared to healthy controls, and explored if sleep related factors are an risk factor for sustained 
attention.. The results of this study are described in Chapter 7. 
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A B S T R A C T
B a c k g r o u n d 
Subsequent nights with partial sleep restriction result in impaired glucose tolerance, but the 
effects on insulin sensitivity have not been characterized. 
O b j e c t i v e
The aim of this study was to evaluate the effect of a single night of partial sleep restriction on 
parameters of insulin sensitivity.
R e s e a r c h  d e s i g n  a n d  m e t h o d s
Nine healthy subjects (five men, four women) were studied once after a night of normal sleep 
duration (sleep allowed from 2300 to 730 h), and once after a night of 4 hours of sleep (sleep 
allowed from 0100 to 0500 h). Sleep characteristics were assessed by polysomnography. Insulin 
sensitivity was measured by hyperinsulinemic euglycemic clamp studies (from 1130 to 1430 h) 
with infusion of [6,6-2H
2
]glucose. 
R e s u l t s
sleep duration was shorter in the night with sleep restriction than in the unrestricted night 
(226±11 vs. 454±9 min, P< 0.0001). Sleep restriction did not affect basal levels of glucose, non-
esterified fatty acids, insulin, or endogenous glucose production. Sleep restriction resulted in 
increased endogenous glucose production during the hyperinsulinemic clamp study compared 
to the unrestricted night (4.4±0.3 vs. 3.6±0.2 μmol x kg lean body mass-1.min-1, P=0.017), 
indicating hepatic insulin resistance. In addition, sleep restriction decreased the glucose 
disposal rate during the clamp (32.5±3.6 vs. 40.7±5.1 μmol x kg lean body mass-1. min-1, P=0009), 
reflecting decreased peripheral insulin sensitivity. Accordingly, sleep restriction decreased the 
rate of glucose infusion by approximately 25% (P=0.001). Sleep restriction increased plasma 
nonesterified fatty acid levels during the clamp study (68±5 vs. 57±4 μmol/L, P=0.005).
C o n c l u s i o n s
Partial sleep deprivation during only a single night induces insulin resistance in multiple 
metabolic pathways in healthy subjects. This physiological observation may be of relevance for 
variations in glucoregulation in patients with type 1 and type 2 diabetes.
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I N T R O D U C T I O N
Sleep plays a key role in the homeostasis of normal glucose metabolism.(1;2) In physiological 
circumstances, glucose metabolism shows a diurnal pattern with intra-individual variations 
in glucose tolerance: glucose utilization is highest during wake and lowest during non-REM 
sleep.(3) Reductions in sleep duration result in impaired glucose tolerance. Epidemiological 
studies documented a strong association between partial sleep restriction and impaired 
glucose tolerance.(4-6) In accordance with these findings, experimental studies showed that 
sleep restriction to only 4 h of sleep during two or more nights reduced glucose tolerance 
by 40%, and reduced the acute insulin response to glucose in healthy subjects by 30%.(7;8) 
However, the effects of only a single night of partial sleep restriction on insulin sensitivity are 
unknown. Moreover, previous studies did not include the assessment of insulin sensitivity by 
the hyperinsulinemic euglycemic clamp method, which is considered to be the golden standard 
for measurement of insulin sensitivity. We hypothesized that even a single night of partial sleep 
deprivation might induce insulin resistance in healthy subjects. Therefore, we compared the 
effects of a single night of partial sleep restriction and of a night of normal sleep duration on 
hepatic and peripheral insulin sensitivity in hyperinsulinemic euglycemic clamp conditions 
combined with tracer dilution of [6,6-2H
2
] glucose. 
S U B j E C T S  A N D  M E T h O D S
S u b j e c t s
Nine healthy lean subjects (five men and four women) were recruited by advertisement. Their 
weight had been stable for at least three months before participation in this study. Subjects 
were instructed not to alter life style habits during the whole study period. All premenopausal 
women were studied in the follicular phase of their menstrual cycle. Exclusion criteria were a 
body mass index >26 kg/m², sleep disorders, habitual sleep duration of less than 6 h or more 
than 9 h, psychiatric disorders, use of sleep medication or of medication affecting glucose 
metabolism. The study was approved by the medical ethical committee of Leiden University 
Medical Center and written informed consent was obtained from all subjects prior to the study.
S t u d y  d e s i g n
Actigraphy (Actiwatch AW7, Cambridge Neurotechnology, UK) was performed to objectively 
measure habitual sleep duration during 7 d before to the actual study, including one weekend. In 
addition, self reported sleep duration and sleep quality were assessed using validated questionnaires 
(Pittsburgh Sleep Quality Index, Epworth Sleepiness scale and Berlin Questionnaire).(9-11) 
The subjects were studied on 3 d, separated by intervals of at least 3 wk. Subjects kept a 
detailed diary of their diet and physical activity for 3 d before each study day and were asked 
to maintain a standardized schedule of bedtimes and mealtimes in accordance with their usual 
habits. They were admitted to our clinical research center the night before each study day, and 
spent 8.5 h in bed from 2300 h to 0730 h on all 3 occasions. Subjects fasted throughout these 
nights from 2200 h. The first study day was included to let the subjects become accustomed to 
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sleeping in our clinical research center. Subjects were randomly assigned to sleep deprivation 
on either the second (n=4) or third (n=5) occasion. 
During the night of sleep restriction, subjects spent 8.5 h in bed, but were only allowed 
to sleep from 0100 h to 0500 h A.M. They were allowed to read or watch movies in an upward 
position during the awake hours, and their wakefulness was monitored and assured if necessary. 
The rationale for essentially broken sleep deprivation from 2300 to 0100 h and from 
0500-0730 h, as opposed to sleep deprivation from 2300 to 03.00 h, or 0300-0730 h, was that 
in both conditions, the time in bed was centered at the same time, i.e. approximately 0300h. 
Slow- wave sleep (i.e. stage III of non-REM sleep) is thought to play the most important role in 
metabolic, hormonal and neurophysiologic changes during sleep. Slow wave sleep mainly occurs 
during the first part of the night, whereas REM sleep predominantly occurs during the latter part 
of the night.(12) We used broken sleep deprivation to achieve a more equal compression of both 
non-REM and REM sleep stages. Moreover, we used the same experimental conditions for partial 
sleep deprivation as previously used in other studies(7;13) to enable comparison of the results.
P o l y s o m n o g r a p h y 
Sleep recordings were performed using a portable PSG recorder (Titanium, Embla Systems, Inc, 
Broomfield, USA). Sleep was visually scored for each of the three nights according to the guidelines 
of the American Association of Sleep Medicine.(14) For this study, the duration of wake, stage I, II, III 
and REM sleep were noted. Total sleep duration was the sum of sleep stages I, II, III and REM.
h y p e r i n s u l i n e m i c  e u g l y c e m i c  c l a m p  s t u d i e s
Hyperinsulinemic euglycemic clamp studies were performed the day after the second and third 
nights. After an overnight fast, a catheter was inserted into an antecubital vein for infusion of 
isotopes, glucose and insulin, and a sampling catheter was inserted into a dorsal hand vein of 
the contralateral arm. For all blood samples, the heated hand technique was used to obtain 
arterialized blood.(15) A primed [17.6μmol.kg-1], continuous [0.22 μmol.kg-1.min-1] infusion of 
[6,6-2H
2
] glucose (Cambridge Isotope Laboratory, Andover, MA) was started at 0830 h, both 
after the night of normal sleep duration and after the night of partial sleep deprivation, after 
basal blood samples had been taken for determination of background glucose enrichment. 
Labeled glucose was infused by a Pilot C syringe pump (Fresenius Vial, Fresenius Kabi, Brezins, 
France). Blood samples were obtained after 160, 170 and 180 min of [6,6-2H
2
] glucose infusion 
for assessment of glucose kinetics in the basal state and concentrations of glucose, insulin and 
plasma non-esterified fatty acids (NEFA). 
Subsequently, infusion of insulin was started, using the method of DeFronzo et al.(16) 
while the infusion of [6,6-2H
2
] glucose continued. Briefly, the infusion of insulin consisted of 
a primed (80 mU. m-2 . min-1 for 5 min and subsequently 40 mU. m-2 . min-1 for 5 min), followed 
by continuous (20 mU. m-2. min-1) infusion of insulin (Actrapid; Novonordisk; Alphen a/d Rijn; 
The Netherlands), dissolved in sterile NaCl 0.9%, using a Pilot C syringe pump (Fresenius Vial, 
France). A variable infusion of glucose 20% enriched with 3% [6,6-2H
2
]glucose was started four 
minutes after the start of insulin infusion. Plasma glucose concentrations were measured with 
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intervals of 5 min with a bedside calibrated glucose analyzer (Accu-Chek; Roche; Mannheim; 
Germany) and the infusion rate of glucose 20% was adjusted in order to keep the plasma 
glucose levels constant at 5.0 mmol/liter during the clamp study. Blood samples were obtained 
after 160, 170 and 180 min of combined insulin and [6,6-2H
2
] glucose infusion for assessment of 
glucose kinetics and of concentrations of glucose, insulin and plasma NEFA. 
A s s a y s
Serum concentrations of glucose were measured using a fully automated Modular P 800 
analyzer (Roche/Hitachi, Mannheim, Germany) with intraassay variations of 1%. Serum insulin 
concentrations were measured by enzyme labeled chemiluminiscent immunometric assay 
(Immulite 2500; Siemens; Germany) with an intraassay coefficient of variation (CV) of 4%. Cortisol 
was analysed on a Modular E-170 immunoanalyser of Roche Diagnostics (Mannheim, Germany). 
Intra- and interassay CV were less than 5% at all measured levels. Glucagon was analysed using an 
immunoradio-metric assay of Millipore (Billerica MA, formerly known as Linco) with a functional 
sensitivity of 20 pg/ml. Intraassay CV was less than 12% and inter-assay CV was less than 15%. NEFA 
were determined spectrophotometri-cally by enzymatic colorimetric acyl-CoA synthase/acyl-CoA 
oxidase assay (WAKO Chemicals, Neuss, Germany) with intra-assay CV of 2.7%. Enrichment of plasma 
[6,6-2H
2
] glucose was determined in a single analytical run, using gas chromatography coupled to 
mass spectrometry, as described previously.(17) All isotope enrichments were measured on a gas 
chromatograph mass spectrometer (model 6890/5973; Hewlett-Packard; Palo Alto; CA). 
C a l c u l a t i o n s
An isotopic steady state was achieved during the final 30 min of the basal period and the final 
30 min of the hyperinsulinemic clamp study. Therefore, the rates of appearance (Ra) and 
disappearance (Rd) of glucose were calculated as the tracer infusion rates divided by the tracer-
to-tracee ratios.(18) Endogenous glucose production during the basal steady state is equal to Ra 
of glucose, whereas endogenous glucose production during the hyperinsulinemic clamp study 
was calculated as the difference between Ra and the glucose infusion rates. 
S t a t i s t i c a l  a n a l y s i s
Data are presented as mean ± SEM. Differences between the effects of the night of normal 
sleep duration and sleep restriction were analyzed by Student’s t test for paired samples. All 
analyses were performed using SPSS for Windows version 16.0 (SPSS, Chicago, IL). Significance 
was accepted at P<0.05.
R E S U L T S 
C l i n i c a l  c h a r a c t e r i s t i c s
Mean age of the subjects (five men, four women) was 44.6 ± 4.9 yr; mean weight was 72.4 ± 2.6 
kg; mean height was 174.6 ± 1.4 cm; and mean body mass index was 23.8 ± 0.8 kg/m2. All subjects 
had normal results on validated questionnaires on sleep characteristics.(9-11) Self-reported sleep 
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duration and recorded habitual sleep duration by actigraphy were not different (450 ± 20 vs 
476 ± 11 min, P=0.19). 
T h e  e f f e c t s  o f  p a r t i a l  s l e e p  r e s t r i c t i o n  o n  p o l y s o m n o g r a p h i c 
p a r a m e t e r s  ( Ta b l e  1 )
Measured sleep duration was considerably shorter in the night with partial sleep restriction, compared 
to the night with normal sleep duration (P< 0.001). The proportion of stage III sleep was higher in the 
sleep-deprived night (P=0.007), whereas the subjects had relatively less stage II sleep (P=0.006). The 
percentages of REM-sleep and wake time during sleep did not differ significantly between nights. 
T h e  e f f e c t s  o f  p a r t i a l  s l e e p  r e s t r i c t i o n  o n  b a s a l  m e t a b o l i c 
p a r a m e t e r s  ( Ta b l e  1 ) 
Compared to normal sleep, partial sleep deprivation did not alter basal levels of glucose, NEFA, insulin, 
glucagon or cortisol measured the following morning. In addition, sleep restriction did not affect 
basal endogenous glucose production assessed by primed, continuous infusion of [6,6-D2 glucose]. 
Table 1. The effects of a night of normal sleep duration and of a night with sleep restricted to 4 hours on sleep 
parameters, basal and insulin-stimulated glucose and fatty acid metabolism measured the following morning 






Total sleep time(min) 454 ± 9 226 ± 11 0.000
Stage I (%) 9.6 ± 1.1 10.7 ± 2.3 0.490
Stage II (5) 41.3 ± 2.5 34.5 ± 3.4 0.006
Stage III (SWS) (%) 25.4 ± 1.8 33.5 ± 3.1 0.007
REM sleep (5) 23.7 ± 1.7 21.3 ± 3.0 0.364
Wake time during sleep (%) 6.8 ±1.5 6.8 ± 2.2 1.0
Basal values
Glucose (mmol/liter) 4.8 ± 0.18 4.8 ± 0.18 0.32
Insulin (mU/liter) 3.1 ± 0.5 3.6 ± 0.6 0.18
NEFA (μmol/liter) 630 ±50 620 ± 50 0.76
Endogenous glucose production (μmol.kgLBM-1.min-1 16.7 ± 0.4 16.7 ± 0.5 0.87
Glucagon (pg/ml) 36 ± 4 35 ± 4 0.888
Cortisol (nmol/liter) 349 ± 59 395 ± 59 0.308
Hyperinsulinemic euglycemic clamp study
Glucose (mmol/liter) 5.0 ± 0.11 4.9 ± 0.9 0.10
Insulin (mU/liter) 22.0 ± 1.5 21.4 ± 1.8 0.30
NEFA (μmol/liter) 57 ± 4 68 ± 5 0.005
Endogenous glucose production (μmol.kgLBM-1.min-1) 3.6 ± 0.2 4.4 ± 0.3 0.017
Glucose Rd (μmol.kgLBM-1.min-1) 40.7 ± 5.1 32.5 ± 3.6 0.009
Glucose infusion rate (μmol.kg LBM-1.min -1) 36.9 ± 5.1 27.8 ± 3.7 0.001
Glucagon (pg/ml) 24 ± 3 25 ± 3 0.590
Cortisol (nmol/liter) 353 ± 47 410 ± 48 0.321
Data are presented as mean ± SEM. Significant differences are shown in bold. LBM, Lean body mass. 
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Figure 1. Individual values obtained during steady state of the hyperinsulinemic euglycemic clamp studies of 
nonesterified fatty acids (NEFA) (A),endogenous glucose production (B), glucose disposal rate (C), and the 
glucose infusion rate (D) after a night of normal sleep duration versus after a night of partial sleep deprivation 
in healthy subjects (n=9). Black horizontal lines represent the mean of the values of 9 subjects. There were 
significant differences (P < 0.05) for all these parameters after partial sleep deprivation.
The effec ts  of  par tial  s leep restric tion on metabolic  parameters during 
hyperinsulinemic euglycemic clamp conditions (Table 1  and f igure 1)
Steady state glucose and insulin levels did not differ between the two clamp studies. Sleep 
restriction resulted in an increase of endogenous glucose production of approximately 22% 
(P=0.017) during the clamp conditions, indicating hepatic insulin resistance. In addition, sleep 
restriction decreased the rate of glucose disposal (Rd) during the clamp by approximately 20% 
(P=0.009), reflecting decreased peripheral insulin sensitivity. Accordingly, the rate of infusion 
of glucose, necessary to maintain plasma glucose levels during the hyperinsulinemic clamp 
study, was approximately 25% lower after the night of reduced sleep duration than after the 
night of normal sleep duration (P=0.001). Finally, the night of partial sleep restriction induced 
an increase of approximately 19% in plasma NEFA levels (P=0.005) during the clamp study, 
indicating decreased insulin sensitivity of lipolysis. 
There were no differences in glucagon or cortisol levels between the steady state conditions 
of the both clamp studies. 
D I S C U S S I O N
The aim of the present study was to assess the effects of partial sleep deprivation during a single 
night on insulin sensitivity in healthy subjects. The results indicate that partial sleep restriction 
during only a single night reduces insulin sensitivity by 19-25% of hepatic and peripheral glucose 
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metabolism, as well as of peripheral lipolysis, reflected by NEFA levels. Therefore, a single night of 
sleep restriction to 4 h induces insulin resistance of multiple metabolic pathways in healthy subjects. 
The results of the present study stress the importance of sleep duration as a physiological 
determinant for insulin sensitivity. The study is unique in several ways. First, the finding that a 
single night of shortened sleep is sufficient to reduce insulin sensitivity in healthy men and women 
is novel. Second, this is the first study detailing the effects of sleep restriction on parameters 
of insulin sensitivity documented during hyperinsulinemic euglycemic clamp conditions with 
isotope dilution of a glucose tracer. Third, we document that insulin sensitivity is reduced in 
different metabolic pathways, i.e. endogenous glucose production, glucose uptake and lipolysis.
The current study extends the observations of previous experimental studies on the effects of 
sleep deprivation on glucose metabolism, summarized in Table 2. These studies covered a range of 
sleep deprivation between 1 h of restriction of sleep during multiple subsequent nights, restriction 
to 4 h of sleep during subsequent nights and finally complete deprivation of sleep. There was no 
significant effect on glucose tolerance if sleep was reduced by only one h.(19) More severe restriction 
of sleep duration to 4 h per night during multiple subsequent nights resulted in decreased glucose 
tolerance.(7;20) Total sleep deprivation also decreased glucose tolerance.(21;22) Apparently, there is a 
threshold of a minimum duration of sleep, which is required for maintenance of normal glucose 
tolerance. Moreover, based on our findings after only a single night of partial sleep deprivation, it 
is tempting to speculate that the negative effects of multiple nights of partial sleep restriction on 
glucose tolerance can be reproduced, at least in part, by only a single night of sleep deprivation.
Table 2. Summary of experimental studies on the effects of sleep deprivation on glucose metabolism
First author, 
year (Ref) Sample size Sleep deprivation Insulin sensitivity Results
VanHelder et al  
(1993) (22)
10 healthy males Total sleep deprivation 
for 60 h
OGTT No differences in plasma 
glucose response to OGTT
20% increase in resting 
plasma insulin levels after 
sleep deprivation




Partial sleep deprivation 
for 6 nights, bedtime 4 
h/night
IVGTT
24 h profile glucose and 
hormone concentrations
40% decrease in glucose 
tolerance after sleep 
deprivation
González-Ortiz 
et al  
(2000)(21)
7 healthy males 
7 healthy women
Total sleep deprivation 
for 24 h
Insulin suppression test 
with octreotide
18% increase in steady state 
glucose concentration 
after sleep deprivation




Time in bed restriction 
for 8 weeks, total sleep 
time 1 h less/night
OGTT No significant effect on 
glucose tolerance
Nedeltcheva 




Mean age 39 yr
Partial sleep 




10% increase in 2-h glucose 
levels and 17.5% decrease in 
insulin sensitivity









19-25% decrease in insulin 
sensitivity in multiple 
metabolic pathways
OGTT = oral glucose tolerance test; IVGTT = intravenous glucose tolerance test
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Our data also indicate that insulin sensitivity is not fixed in healthy subjects, but, rather, 
depends on the duration of sleep in the preceding night. These observations extend previous 
studies, which documented consistent effects of short term variations in dietary macronutrient 
composition, dietary caloric content and short term fasting on insulin sensitivity in healthy 
subjects.(17;23;24) Other studies have indicated effects of exercise in preceding days on insulin 
sensitivity.(25) Therefore, environmental factors including previous sleep duration, exercise, 
dietary macronutrient composition and content modulate insulin sensitivity in healthy subjects. 
The current study was aimed at assessing the effects of a single night of sleep deprivation 
on parameters of insulin sensitivity. Unfortunately, the study was not designed to elucidate the 
underlying mechanisms of this effect of partial sleep deprivation. We observed no effects of partial 
sleep deprivation on cortisol and glucagon levels. Schmid et al.(26) documented that a single night 
of sleep restriction to 4.5 h reduced basal plasma glucagon and cortisol levels on the following 
morning, but did not affect basal glucose, insulin, C-peptide epinephrine, norepinephrine, or 
GH levels. Apparently, endocrine changes after a single night of partial sleep deprivation do not 
provide a simple explanation for the induction of insulin resistance. Spiegel et al.(7) documented 
that subsequent nights of partial sleep deprivation increased cortisol levels during 24 h whereas 
Nedeltcheva et al.(20) did not find a major effect on cortisol levels. Nedeltcheva et al. documented 
that prolonged partial sleep deprivation induced a modest increase in 24-h epinephrine and 
nighttime norepinephrine levels. In accordance, Irwin et al.(27) documented that plasma levels 
of epinephrine increased in association with nocturnal awakening. Therefore, sequential nights 
of partial sleep deprivation induce modest changes in endocrine homeostasis and in glucose 
tolerance, but the relations between these phenomena are uncertain. Alternatively, it is 
possible that partial sleep deprivation decreases insulin sensitivity by altering the activity of the 
autonomous nervous system. However, this is a difficult area of investigation. Previous studies 
have documented an increased sympathetic tone derived from recordings of heart rate variability 
after sleep deprivation for a single or consecutive nights.(13;28) However, it is not known to which 
extent partial sleep loss induces comparable increases in sympathetic activity at all peripheral 
sites. Consequently, the relationship between elevated sympathovagal balance at the level of the 
heart and the sympathetic outflow to liver, muscles, and adipose tissue is uncertain.(13)
What are the implications of the present observations? Sleep duration has shortened 
considerably in western societies in the past decades.(5;29) Simultaneously, there has been an 
increase in the prevalence of insulin resistance and type 2 diabetes. The current and other 
studies (Table 2) indicate that shortened sleep duration is a factor that contributes to glucose 
intolerance and, even after a single night, to insulin resistance. 
It is also tempting to speculate to which extent variations in sleep duration may be involved 
in the intraindividual variations in glucose levels that are present especially in patients with 
type 1 diabetes. At present it is unclear whether interventions aimed at optimization of sleep 
duration may be beneficial in stabilizing glucose levels in patients with diabetes. 
In conclusion, the present study indicates that partial sleep restriction, even during a single 
night, decreases insulin sensitivity of multiple metabolic pathways in healthy subjects. 
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A B S T R A C T
B a c k g r o u n d
Sleep restriction results in decreased insulin sensitivity and glucose tolerance in healthy 
subjects. We hypothesized that sleep duration is a determinant of insulin sensitivity in patients 
with type 1 diabetes.
R e s e a r c h  d e s i g n  a n d  m e t h o d s
we studied seven patients (three men, four women) with type 1 diabetes: mean age 44±7 yr, 
body mass index (BMI) 23.5±0.9 kg/m2 and HbA
1c
 7.6±0.3%. They were studied once after a 
night of normal sleep duration, and once after a night of only 4 h of sleep. Sleep characteristics 
were assessed by polysomnography. Insulin sensitivity was measured by hyperinsulinemic 
euglycemic clamp studies with infusion of [6,6-2H
2
] glucose. 
R e s u l t s
Sleep duration was shorter in the night with sleep restriction than in the unrestricted night (469±8.5 
vs. 222±7.1 min, P= 0.02). Sleep restriction did not affect basal levels of glucose, non-esterified fatty 
acids (NEFAs) or endogenous glucose production. Endogenous glucose production during the 
hyperinsulinemic clamp was not altered during the night of sleep restriction compared with the 
night of unrestricted sleep (6.2±0.8 vs. 6.9±0.6 μmol.kg lean body mass-1.min-1, NS). In contrast, 
sleep restriction decreased the glucose disposal rate during the clamp (25.5±2.6 vs. 22.0±2.1 μmol.
kg lean body mass-1.min-1, P=0.04), reflecting decreased peripheral insulin sensitivity. Accordingly, 
sleep restriction decreased the rate of glucose infusion by ~21% (P=0.04). Sleep restriction did not 
alter plasma NEFA levels during the clamp (143±29.vs. 133±29 μmol/l, NS).
C o n c l u s i o n s
Partial sleep deprivation during a single night induces peripheral insulin resistance in these 
seven patients with type 1 diabetes. Therefore, sleep duration is a determinant of insulin 
sensitivity in patients with type 1 diabetes.
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I N T R O D U C T I O N
Intensive insulin therapy is essential for optimal glucoregulation in type 1 diabetes, because the 
degree and duration of hyperglycemia determine the incidence of complications.(1) However, 
glucoregulation cannot be normalized in patients with type 1 diabetes, as reflected in relatively 
large intra-individual variations of blood glucose levels. Subtle intra-individual variations in 
glucoregulation and insulin sensitivity in these patients depend on variations in physiological 
determinants, such as dietary factors and exercise.(2;3) In contrast to healthy subjects, however, 
patients with type 1 diabetes mellitus are unable to compensate for these physiological 
variations, other than by variation of the dose of exogenous insulin. 
Normal glucose homeostasis shows a diurnal pattern with variations in glucose tolerance, in 
which sleep characteristics plays a key role.(4) In this respect, sleep duration may be particularly 
relevant because sleep curtailment is a common aspect of our modern 24-h society.(5;6) A reduction 
in sleep duration impairs glucose tolerance in healthy subjects.(7) The effects of reduction of sleep 
duration on insulin sensitivity have not been studies in patients with type 1 diabetes. 
We hypothesize that partial sleep restriction decreases insulin sensitivity in patients with type 
1 diabetes, which may contribute to intra-individual variations in glucoregulation. Therefore, we 
compared the effects of a single night of reduced sleep duration with those of a night of normal sleep 
duration on hepatic and peripheral insulin sensitivity, as assessed by hyperinsulinemic euglycemic 
clamp studies combined with tracer dilution of [6,6-2H
2
] glucose in patients with type 1 diabetes.
R E S E A R C h  D E S I G N  A N D  M E T h O D S
S u b j e c t s
We included nine patients (five men and four women) with type 1 diabetes on stable continuous 
subcutaneous insulin pump therapy. Diagnostic criteria for type 1 diabetes were past or present 
positive antibodies against GAD or islet cells and plasma free C-peptide levels <0.3 nmol/l. All 
participants were screened in our outpatient clinic prior to the study. Their weight had been 
stable for at least 3 months prior to participation in this study. A1C levels had been below 
8.5 % during the year prior to the start of the study. Exclusion criteria were a BMI>26 kg/m², 
clinical signs of autonomic neuropathy, known sleep disorders, habitual sleep duration of less 
than 6 h or more than 9 h, psychiatric disorders, use of sleep medication, β-blocking agents 
or prokinetic drugs. All patients had normal blood pressure and serum creatinine levels, and 
urinary microalbumin excretion rated below 30 mg/24 h. The study was approved by the 
medical ethical committee of Leiden University Medical Center and written informed consent 
was obtained from all subjects prior to the study.
The subjects were studied on 3 days, separated by intervals of at least 3 weeks. Subjects kept 
a detailed diary of their diet and physical activity for 3 days prior to each study day and were 
asked to maintain a standardized schedule of bedtimes and mealtimes in accordance with their 
usual habits. Actigraphy (Actiwatch AW7, Cambridge Neurotechnology, U.K.) was performed 
to objectively assess patterns of habitual active and inactive (sleep) periods for 7 days prior to 
the actual study, including one weekend. In addition, self- reported sleep duration and sleep 
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quality were assessed using validated questionnaires (Pittsburgh Sleep Quality Index, Epworth 
Sleepiness scale and Berlin Questionnaire).(8-10)
Subjects were admitted to our clinical research center the night preceding each study day, 
and spent 8.5 h in bed from 2300 h to 0730 h on all three occasions. Subjects fasted throughout 
these nights from 2200 h onwards. The first study day served to let subjects become 
accustomed to sleep conditions in a research setting. The optimal overnight infusion rate of 
insulin was determined in each subject prior to the start of the study. Subsequently, this same 
individualized infusion rate was used in both sleeping experiments. Subjects were instructed 
not to alter life style habits during the study period. Premenopausal women were studied in the 
follicular phase of their menstrual cycle.
Subjects were randomly assigned to partial sleep deprivation on either the second (n=4) or 
third (n=5) study occasion. 
During the night of sleep restriction, subjects also spent 8.5 h in bed, but were only allowed 
to sleep from 0100 h to 0500 h. They were allowed to read or watch movies in an upward 
position, and their wakefulness was monitored and assured if necessary.
P o l y s o m n o g r a p h y 
Sleep recordings were visually scored for each of the three nights according to the guidelines of 
the American Association of Sleep Medicine (AASM).(11) In short, scoring of sleep stages depends 
on electroencephalography, eye movements, and submental muscle activity. To detect possible 
sleep disorders that might affect the study, respiratory movements were recorded by measurement 
of changes in nasal pressures and of truncal respiratory movements. Recordings were made using 
a portable polysomnograhy (PSG) recorder (Titanium; Embla Systems, Broomfield, CO). Sleep 
and wake stages were visually scored in consecutive epochs of 30 s, resulting in a list of epochs 
spent in wake, stage I (drowsiness), II, III and rapid-eye movement (REM) dream sleep. The time 
at which subjects went to bed and turned out the lights as well as times of getting out of bed 
were noted. The lists of stages were used to calculate the duration of time spent each night in the 
above-mentioned sleep and wake stages. These durations were also expressed as percentages of 
total sleep duration, defined as the summed duration of sleep stages I, II, III and REM.
h y p e r i n s u l i n e m i c  e u g l y c e m i c  c l a m p  s t u d i e s 
Hyperinsulinemic euglycemic clamp studies were performed the day following the second and 
third study occasions. After an overnight fast, a catheter was inserted into an antecubital vein 
for infusion of isotopes, glucose and insulin, and a sampling catheter was inserted into a dorsal 
hand vein of the contra lateral arm. For all blood samples, the heated hand technique was used to 
obtain arterialized blood.(12) A primed [17.6 μmol/kg-1] continuous [0.22 μmol.kg-1.min-1] infusion 
of [6,6-2H
2
] glucose (Cambridge Isotope Laboratory, Andover, MA) was started at 0830 h, after 
basal blood samples had been taken for determination of background glucose enrichment. 
Labeled glucose was infused by a Pilot C syringe pump (Fresenius Vial, Brezins, France). Blood 
samples were obtained after 160,170 and 180 min of [6,6-2H
2
] glucose infusion for assessment 
of glucose kinetics in the basal state and concentrations of glucose and plasma non-esterified 
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fatty acids (NEFAs). Subsequently, administration of subcutaneous insulin was stopped and 
infusion of intravenous insulin was started, using the method of DeFronzo et al.(13) Briefly, this 
consisted of a primed (80 mU.m-2 .min-1 for 5 minutes and subsequently 40 mU.m-2 .min-1 for 
5 min), followed by continuous (20 mU.m-2 .min-1) infusion of insulin (Actrapid, Novo Nordisk, 
Alphen a/d Rijn, The Netherlands), dissolved in sterile NaCl 0.9 %, using a Pilot C syringe 
pump (Fresenius Vial, France). A variable infusion of glucose 20% enriched with 3% [6,6-2H
2
] 
glucose was started 4 min after the start of insulin infusion. Plasma glucose concentrations 
were measured with intervals of 5 min with a bedside calibrated glucose analyzer (Accu-Chek, 
Roche, Mannheim, Germany) ,and the infusion rate of glucose 20% was adjusted in order to 
keep the plasma glucose levels constant at 5.0 mmol/l during the clamp study. Blood samples 
were obtained after 150,160,170 and 180 min of combined insulin and [6,6-2H
2
] glucose infusion 
for assessment of glucose kinetics and of concentrations of glucose, insulin and plasma NEFA. 
B i o c h e m i c a l  a n a l y s i s
Serum concentrations of glucose were measured using a fully automated Modular P 800 
analyzer (Roche/Hitachi; Mannheim, Germany) with intra-assay variations of 1%. Serum insulin 
concentrations were measured by enzyme labeled chemiluminescent immunometric assay 
(Immulite 2500; Siemens; Bad Nauheim, Germany) with an intra-assay coefficient of variation (CV) of 
4%. NEFA were determined spectrophotometrically by enzymatic colorimetric acyl-CoA synthase/
acyl-CoA oxidase assay (WAKO Chemicals, Neuss, Germany) with intra-assay CV of 2.7%. Enrichment 
of plasma [6,6-2H
2
]glucose was determined in a single analytical run, using gas chroma-tography 
coupled to mass spectrometry, as described previously.(14) All isotope enrichments were measured 
on a gas chromatograph mass spectrometer (model 6890/5973, Hewlett-Packard, Palo Alto, CA). 
C a l c u l a t i o n s
Isotopic steady state was achieved during the final 30 min of the basal period and the final 
30 min of the hyperinsulinemic clamp study. Therefore, the rates of appearance (Ra) and 
disappearance (Rd) of glucose were calculated as the tracer infusion rates divided by the 
tracer-to-tracee ratios. Endogenous glucose production (EGP) during the basal steady state is 
equal to Ra of glucose, whereas EGP during the hyperinsulinemic clamp study was calculated as 
the difference between Ra and the glucose infusion rates. 
S t a t i s t i c a l  a n a l y s i s
Data are presented as mean ± SEM. Differences between the effects of the night of normal 
sleep duration and sleep restriction were analyzed by the Wilcoxon signed rank test for paired 
samples. All analyses were performed using SPSS for Windows version 16.0 (SPSS, Chicago, IL). 
Significance was accepted at p<0.05.
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R E S U L T S
C l i n i c a l  c h a r a c t e r i s t i c s
The results of two of the nine patients were excluded, because of nocturnal hypoglycaemia and 
subsequent nocturnal hyperglycaemia during the study (n=1), and because of the presence of a 
previously undetected sleep apnea syndrome (n=1). Therefore, the analyses included the data 
of seven patients (three men) for analysis. Mean age of these seven subjects was 44.3±6.6 years, 
mean weight 72.0±4.0 kg, mean height 175±3 cm and mean BMI 23.5±0.9 kg/m2. Mean A1C of 
the patients was 7.6±0.3% and mean duration of diabetes was 23±3.5 yr. All subjects had normal 
results on validated sleep questionnaires. Self-reported sleep duration and recorded habitual 
sleep duration by actigraphy were not different (475±8 vs. 490±7 min, P=0.12). 
E f f e c t s  o f  p a r t i a l  s l e e p  r e s t r i c t i o n  o n  p o l y s o m n o g r a p h i c  p a r a m e t e r s
Sleep duration was considerably shorter in the night with partial sleep restriction, compared 
to the night with normal sleep duration (P=0.02) (Table 1). Sleep in the sleep-deprived night 
showed a higher proportion of stage III sleep (P=0.02) and a lower proportion of REM sleep 
(P=0.04). The proportions of time spent in other stages did not differ between the conditions. 
Table 1. The effects of a normal night of sleep and of a night with sleep restricted to 4 hours on sleep parameters 
assessed by polysomnography, basal and insulin stimulated glucose and fatty acid metabolism in 7 patients with 
type 1 diabetes.
Normal sleep Partial sleep deprivation P value
Sleep parameters
TST (min) 469 ± 8.5 222 ± 7.1 0.02
Stage 1 (% of TST) 10.6 ± 1.0 10.2 ± 2.1 0.49
Stage 2 (% of TST) 44.4 ± 2.8 40.4 ± 2.4 0.13
Stage 3 (% of TST) 22.7 ± 3.4 35.3 ± 4.4 0.02
REM sleep (% of TST) 22.2 ± 1.7 13.7 ± 2.3 0.04
Wake time during sleep (% of total sleep period) 4.2 ± 0.7 5.4 ± 2.3 0.87
Basal values
Glucose (mmol/L) 7.2 ± 1.0 6.7 ± 1.4 0.87
NEFA (umol/L) 673 ± 125 591 ± 99 0.35
Endogenous glucose production (μmol.kgLBM-1.min-1 ) 17.6 ± 0.9 16.3 ± 1.0 0.31
Hyperinsulinemic euglycemicclamp study
Glucose (mmol/l) 5.1 ± 0.2 5.2 ± 0.1 0.23
Insulin  (mU/l) 24.0 ± 2.2 24.9± 1.5 0.40
NEFA (umol/l) 143 ± 29 133 ± 29 0.69
EGP  (μmol.kgLBM-1.min-1 ) 6.2 ± 0.8 6.9 ± 0.6 0.74
Glucose Rd  (μmol.kgLBM-1.min-1 ) 25.5 ± 2.6 22.0 ± 2.1 0.04
Glucose infusion rate(μmol.kgLBM-1.min-1 ) 19.0 ± 2.9 14.9 ± 2.1 0.04




Figure 1. Individual values obtained during steady state of the hyperinsulinemic euglycemic clamp studies of 
NEFAs (A), EGP (B), glucose disposal rate (C), and the glucose infusion rate (D) after a night of normal sleep 
duration versus after a night of partial sleep deprivation in patients with type 1 diabetes (n=7). Black horizontal 
lines represent the mean of the values of seven subjects. 
E f f e c t s  o f  p a r t i a l  s l e e p  r e s t r i c t i o n  o n  b a s a l  m e t a b o l i c  p a r a m e t e r s 
The mean overnight rate of subcutaneous infusion of insulin was 0.7 IE/h and was identical in 
both conditions (Table 1). Compared with normal sleep duration, partial sleep deprivation did not 
alter basal levels of glucose or NEFA measured the following morning. In addition, partial sleep 
restriction did not affect basal EGP assessed by primed, continuous infusion of [6,6-2H
2
 glucose]. 
T h e  e f f e c t s  o f  p a r t i a l  s l e e p  r e s t r i c t i o n  o n  m e t a b o l i c  p a r a m e t e r s 
d u r i n g  h y p e r i n s u l i n e m i c  e u g l y c e m i c  c l a m p  c o n d i t i o n s 
Steady state glucose and insulin levels did not differ between the two clamp studies (Table 1 and 
Fig.1). Sleep restriction did not affect EGP during the clamp conditions. However, sleep restriction 
decreased the rate of glucose disposal (Rd) during the clamp by ~14% (P=0.04). Accordingly, 
the rate of infusion of glucose, necessary to maintain constant plasma glucose levels during the 
hyperinsulinemic clamp study, was ~21% lower after the night of reduced sleep duration than after 
the night of normal sleep duration (p=0.04), reflecting decreased peripheral insulin sensitivity. 
There was no significant effect of partial sleep restriction on plasma NEFA levels.
C O N C L U S I O N S
In this study, we assessed the effects of a single night of partial sleep restriction on insulin sensitivity 
in patients with type 1 diabetes. The results indicate that only a single night of partial sleep restriction 
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reduces insulin sensitivity of insulin stimulated glucose uptake by 14-21%. Partial sleep restriction did 
not significantly affect basal glucose metabolism. We conclude that sleep duration is a determinant of 
peripheral insulin sensitivity in patients with type 1 diabetes. In the current study, we included data of 
only seven patients with type 1 diabetes. The strictly controlled design of this pathophysiological study 
in combination with the fact that each subject served as his/her own control enabled us to establish 
subtle effects of partial sleep deprivation on parameters of insulin sensitivity. Nonetheless, larger 
numbers of subjects are required to assess the involvement of relevant patient characteristics such 
as sex, age, and antecedent glucoregulation on the effects of sleep restriction on insulin sensitivity. 
This is the first study that documents an adverse effect of partial sleep restriction on insulin 
sensitivity in patients with type 1 diabetes. In healthy subjects, sleep restriction induces insulin 
resistance and reduces glucose tolerance.(7;15) By analogy, it can be expected that sleep restriction 
increases postprandial glucose levels in patients with type 1 diabetes in the absence of concurrent 
adaptations of the dose of exogenous insulin. Insulin sensitivity is not static but varies over time 
within individuals. This is also reflected by the current study in patients with type 1 diabetes. Several 
epidemiological studies documented an association between chronic partial sleep restriction and 
development of insulin resistance and type 2 diabetes.(5;16;17) Therefore, exposure to chronic sleep 
restriction might contribute to insulin resistance in patients with type 1 diabetes. In turn, insulin 
resistance is associated with an increased risk for microvascular and macrovascular complications in 
type 1 diabetes.(18) Unfortunately, the current study was not designed to elucidate the mechanisms 
involved in the induction of insulin resistance by partial sleep deprivation. A single night of partial 
sleep restriction to 4.5 h does not cause endocrine changes that simply explain the induction of 
insulin resistance.(19) Subsequent nights of partial sleep deprivation induce subtle changes in cortisol 
and catecholamine secretion.(7;15;20) However, the relations between these effects of sleep deprivation 
on endocrine homeostasis and glucose tolerance are uncertain. Partial sleep deprivation for a single 
and subsequent nights increased the sympathetic tone based on recordings of heart rate variability 
after sleep deprivation.(21;22) However, the relationship between elevated sympathovagal balance at 
the level of the heart and the sympathetic outflow to liver, muscles, and adipose tissue is uncertain.(21)
Interestingly, in addition to sleep duration, the composition of sleep in terms of sleep stages 
is also a determinant of insulin sensitivity. Selective suppression of slow- wave sleep, without any 
change in total sleep duration, decreased glucose tolerance.(23) The differential effects of altered 
sleep composition versus decrease total sleep duration on insulin sensitivity await further study. 
Data on sleep physiology and sleep disturbances in patients with type 1 diabetes are rare. 
Jauch-Chara et al.(24) reported alterations in neuroendocrine sleep architecture and a trend 
towards less slow wave sleep in 14 patients with type 1 diabetes. Children with type 1 diabetes 
have a more disrupted sleep than healthy children.(25) If type 1 diabetes indeed causes disruption 
of sleep patterns, this may in turn impair glucose regulation, creating a vicious circle. 
In conclusion, the present study indicates that partial sleep restriction decreases insulin 
sensitivity of insulin-mediated glucose uptake in patients with type 1 diabetes. It is important 
to further assess the relation between sleep physiology and glucoregulation in patients with 
type 1 diabetes. Sleep duration might become another therapeutic target in type 1 diabetes to 
improve glucoregulation in type 1 diabetes. 
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A B S T R A C T
B a c k g r o u n d
A single night of partial sleep deprivation reduced insulin sensitivity in healthy subjects. 
Curtailment of slow wave sleep (SWS) during subsequent nights reduces glucose tolerance in 
healthy subjects. We hypothesized that the effect of a single night of sleep restriction on insulin 
sensitivity could be due to a reduction in total duration of SWS.
A i m  o f  t h e  s t u d y
To assess the effects of one single night of selective SWS suppression on insulin sensitivity, 
assessed by the hyperinsulinemic euglycemic clamp, in healthy controls.
M e t h o d s
We assessed the effect of two nights of normal sleep duration, but with normal versus 
selectively reduced SWS on insulin sensitivity in 10 healthy controls. Mean age was 32±4 yr, 
and mean BMI was 23.2±0.5 kg/m2. Sleep parameters were determined by polysomnography. 
Changes in autonomic balance were assessed by analysis of heart rate variability (HRV). SWS 
was suppressed by delivering acoustic tones of varying frequency, without awakening the 
subjects. The following morning, insulin sensitivity of glucose metabolism was assessed by 
hyperinsulinemic euglycemic clamp studies with infusion of [6,6-2H
2
] glucose. 
R e s u l t s
The duration of SWS was decreased by 63% (P< 0.001), without reduction in total sleep duration. 
Nonetheless, selective suppression of SWS did not alter basal glucose levels or postabsorptive 
endogenous glucose production. During hyperinsulinemic clamp conditions, selective SWS 
suppression did not result in differences in glucose infusion rates or glucose disposal rates. 
In addition, SWS suppression did not alter plasma nonesterified fatty acid levels during 
hyperinsulinemia. SWS suppression increased the low frequency/ high frequency (LF/HF) ratio 
of HRV, indicating a shift towards sympathetic tone.
C o n c l u s i o n s
A single night of selective SWS suppression did not affect insulin sensitivity in healthy controls. 
Therefore, the reduction in insulin sensitivity induced by partial sleep deprivation in healthy 
subjects cannot merely be explained by a reduction in SWS.
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I N T R O D U C T I O N 
Shortening of sleep duration is associated with decreased insulin sensitivity in healthy subjects.(1-3) 
As selective disruption of slow-wave sleep (SWS) during subsequent nights decrease glucose 
tolerance by ~23% in healthy subjects(4) and previous literature showed the clear restorative role 
of SWS in glucose metabolism(5-7), SWS may be the most relevant sleep stage for the regulation 
of glucose metabolism. Human sleep is composed of rapid-eye movement (REM) sleep and 3 
stages of non-rapid-eye movement (NREM) sleep. Stage 3 NREM sleep is also known as SWS.(8) 
During SWS, changes occur in endocrine, metabolic and brain activity.(9;10) The autonomic nervous 
system switches from sympathetic dominance during REM sleep to parasympathetic dominance 
in SWS sleep.(11) Disruptions in SWS are likely to alter the autonomic balance, in sense of increasing 
sympathetic tone. The autonomic nervous system could therefore be an essential pathway 
through which sleep affects endocrine and metabolic function, including glucose metabolism. 
We previously showed that a single night of partial sleep deprivation decreased insulin 
sensitivity by ~20% in healthy subjects and patients with T1DM.(2;12) We hypothesized that this 
could be, at least in part, due to a reduced duration of SWS. Therefore, we studied the effects 
of a single night of selective SWS suppression on insulin sensitivity and autonomic function in 
healthy subjects. Insulin sensitivity was assessed by hyperinsulinemic euglycemic clamp studies 
combined with tracer dilution of [6,6-²H
2
] glucose. 
S U B j E C T S  A N D  M E T h O D S 
S u b j e c t s
Eleven healthy subjects (6 men) were asked to participate in this study. All subjects were lean 
(BMI 20-26 kg/m²) and their weight had been stable for at least 3 months prior to participation 
in this study. Exclusion criteria were known sleep disorders, habitual sleep duration of less than 
6h or more than 9h, shift work, psychiatric disorders, and use of sleep medication, β-blocking 
agents or pro-kinetic drugs. All healthy subjects had normal results on the following 
validated questionnaires, the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, Berlin 
Questionnaire and Hospital Anxiety and Depression Scale.(13-15) We studied premenopausal 
women in the follicular phase of their menstrual cycle. This study was approved by the medical 
ethical committee of the Leiden University Medical Center, and written informed consent was 
obtained from all subjects prior to the study. 
S t u d y  d e s i g n
Subjects were studied on two days, with an interval of at least two weeks. Subjects kept a 
detailed diary of their diet and physical activity for three days prior to each study day and were 
asked to maintain a standardized schedule of bedtimes and mealtimes in accordance with their 
usual habits. Subjects were admitted to our clinical research center the night preceding each 
study day, and spent 8.5 hr in bed from 23:00 h to 07:30 h on both occasions. Subjects fasted 
throughout these nights from 22:00 h onwards. Subjects were randomly assigned to selective 
SWS suppression on either the first or second night. The same basal rate of subcutaneous insulin 
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infusion in patients with type 1 diabetes was used on both study occasions. To obtain glucose 
profiles during each night and to document euglycemia in patients with type 1 diabetes, a 
continuous glucose monitoring system (iPro®2, Medtronic) was inserted. 
P o l y s o m n o g r a p h y  a n d  S w S  s u p p r e s s i o n
Sleep was visually scored by an experienced observer for each night according to the guidelines 
of the American Association of Sleep Medicine (AASM),that rely on electroencephalography, 
eye movements, and submental muscle activity. To detect as yet unknown sleep disorders, leg 
movements and respiratory movements were recorded according to the same guidelines.(16) 
Recordings were made using a portable PSG recorder (Titanium, Embla Systems, Inc, Broomfield, 
USA). The times at which subjects went to bed and turned out the lights as well as times of 
getting out of bed were noted. The duration of time spent each night in each stage was noted 
in min and expressed as percentages of total sleep duration (i.e. the summed duration of 
REM and NREM sleep). During the night of SWS suppression, we aimed to substitute SWS with 
stage 1 or 2 NREM sleep, without changing total sleep duration. Awakenings were therefore 
carefully avoided. During the night of selective SWS suppression, acoustic stimuli of increasing 
intensity were delivered. Subjects slept in a room and were monitored by an experienced sleep 
technician in an adjacent room. An acoustic stimulus was delivered through two speakers in 
the patient’s room, whenever two delta waves appeared in a 30 sec epoch. The equipment was 
designed to deliver sounds in increasing volume, starting with an acoustic tone of 40 dB and 
increasing with increments of 10 dB, if SWS did not disappear. If there was no response on the 
maximum acoustic tone of 110 dB, the laboratory worker knocked on the door or entered the 
room and tapped the subject on the shoulder. 
h e a r t  r a t e  v a r i a b i l i t y  a n a l y s i s
Changes in autonomic balance were assessed by analysis of heart rate variability (HRV). Heart rate 
(HR) (beats/min) was continuously recorded using a single lead ECG during the entire sleep period. 
HRV was estimated by calculating the mean and SD of consecutive R-R intervals; spectral analysis was 
done using a fast Fourier transformation using a Hamming window after cubic spline interpolating 
of RR intervals and resampling the signal at 3 Hz Power was calculated for the low frequency (LF, 
0.04–0.15 Hz) and high frequency (HF, 0.15–0.4 Hz) bands. Total power was calculated by adding 
the LF and HF power values. The LF/HF ratio was calculated and used as an index of sympathovagal 
balance. For each sleep stage, HR, LF and HF power and LF/HF ratio were calculated.
h y p e r i n s u l i n e m i c  e u g l y c e m i c  c l a m p  s t u d i e s
Hyperinsulinemic euglycemic clamp studies were performed the next day after each night at 
08:30 hr in each subject. After an overnight fast, a catheter was inserted into an antecubital 
vein for infusion of isotopes, glucose and insulin, and a sampling catheter was inserted 
into a dorsal hand vein of the contra lateral arm. For all blood samples, the heated hand 
technique was used to obtain arterialized blood.(17) A primed [17.6 μmol.kg-1] continuous 
[0.22 μmol.kg-1.min-1] infusion of [6,6-2H
2
] glucose (Cambridge Isotope Laboratory, Andover, 
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USA) was started at 08:30 h after basal blood samples had been taken for determination of 
background glucose enrichment. Labeled glucose was infused by a Pilot C syringe pump 
(Fresenius Vial, France). Blood samples were obtained after 160,170 and 180 min of [6,6-2H
2
] 
glucose infusion for assessment of glucose kinetics in the basal state. Subsequently, infusion of 
intravenous insulin was started, using the method of DeFronzo et al.(18) Briefly, this consisted of 
a primed (80 mU.m-2 .min-1 for 5 minutes and subsequently 40 mU.m-2 .min-1 for 5 min), followed 
by continuous (20 mU.m-2 .min-1) infusion of insulin (Actrapid, Novonordisk, Alphen a/d Rijn, 
The Netherlands), dissolved in sterile NaCl 0.9%, using a Pilot C syringe pump (Fresenius Vial, 
France). A variable infusion of glucose 20% enriched with 3% [6,6-2H
2
] glucose was started 
four min after the start of insulin infusion. Plasma glucose concentrations were measured with 
intervals of 5 min with a bedside calibrated glucose analyzer (Accu-Check, Roche, Mannheim, 
Germany) and the infusion rate of glucose 20% was adjusted in order to keep the plasma 
glucose levels constant at 5.0 mmol/L during the clamp study. Blood samples were obtained 
after 150, 160, 170 and 180 min of combined insulin and [6,6-2H
2
] glucose infusion for assessment 
of glucose kinetics and of concentrations of glucose and insulin. 
B i o c h e m i c a l  a n a l y s i s
Serum concentrations of glucose were measured using a fully automated Modular P 800 analyzer 
(Roche/Hitachi, Mannheim, Germany) with intra-assay variations of 1%. Serum insulin concentrations 
were measured by enzyme labeled chemiluminescentimmunometric assay (Immulite 2500, 
Siemens, Germany) with an intra-assay coefficient of variation (CV) of 4%. Enrichment of plasma 
[6,6-2H
2
]glucose was determined in a single analytical run, using gas chromatography coupled to 
mass spectrometry, as described previously.(19) All isotope enrichments were measured on a gas 
chromatograph mass spectrometer (model 6890/5973, Hewlett-Packard, Palo Alto, CA).
C a l c u l a t i o n s
Isotopic steady state was achieved during the final 30 min of the basal period and the final 30 
min of the hyperinsulinemic euglycemic clamp study. Therefore, the rates of appearance (Ra) 
and disappearance (Rd) of glucose were calculated as the tracer infusion rates divided by the 
tracer-to-tracee ratios.(20) Endogenous glucose production (EGP) during the basal steady state 
is equal to Ra of glucose, whereas EGP during the hyperinsulinemic clamp study was calculated 
as the difference between Ra and the glucose infusion rates. 
S t a t i s t i c a l  a n a l y s i s
Data are presented as mean±SEM. Differences in duration of sleep stages and parameters of 
insulin sensitivity between a night of normal sleep and a night with selective SWS suppression 
were analyzed by Student’s t test for paired samples. All analyses were performed using SPSS for 
Windows version 16.0 (SPSS, Chicago, IL, USA). Significance was accepted at P<0.05.
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Table 1. Effects of selective SWS suppression on heart rate variability in 10 healthy controls 
Sleep stage
hR (beats/min) LF/hF ratio
Normal sleep SwS P-value Normal sleep SwS P-value
Wake 62 ± 1.1 67 ± 1.2 0.02 2.1± 0.9 1.9± 0.2 NS
Stage 1 58 ± 0.9 57± 0.9 NS 1.4± 0.2 2.0± 0.2 NS
Stage 2 55 ± 0.8 56±0.9 NS 1.2± 0.2 1.9± 0.2 0.05
Stage 3(SWS) 55 ± 0.8 57± 0.9 0.05 0.8± 0.1 1.9± 0.2 0.001
REM 57 ±0.9 59± 1.0 0.04 2.3± 0.3 2.4± 0.3 NS
Data are presented as mean ±SEM. HR, heart rate; LF, low frequency; HF, high frequency; SWS, slow wave sleep; 
NS, non-significant.
Figure 1. Effect of selective SWS suppression on sleep parameters in 10 healthy subjects. White bars represent 
duration of sleep phases during normal sleep and black bars represent duration of sleep phases during selective 
SWS suppression. TST, total sleep time; S1, NREM stage 1; S2, NREM stage 2; S3, NREM stage 3
R E S U L T S
C l i n i c a l  c h a r a c t e r i s t i c s 
The results of one male control were excluded, because of a four-fold increase in wake time 
during the night of selective SWS suppression. Therefore, the analysis included data 10 healthy 
subjects (5 men). Mean age was 32± 4 yr; mean BMI was 23.2 ± 0.5 kg/m2. 
E f f e c t s  o f  S w S  s u p p r e s s i o n  o n  s l e e p  p a r a m e t e r s  ( F i g u r e  1 )
In the night of SWS suppression, the duration of stage 3 NREM sleep decreased by 63% (P<0.001), 
compared to the control night. There were no significant differences in total sleep duration and 
duration of nocturnal wake time between both nights. SWS suppression was associated with an 
increase in the duration of stage 2 NREM sleep by 51% (P<0.001).
E f f e c t s  o f  S w S  s u p p r e s s i o n  o n  h e a r t  r a t e  v a r i a b i l i t y  ( Ta b l e  1 )
During the night of SWS suppression, HRV was significantly elevated during wake, stage 3 NREM 
and REM sleep. Furthermore, SWS suppression increased the LF/HF ratio in stage 2 and 3 NREM 
sleep, indicating a shift towards sympathetic dominance during the night of SWS suppression. 
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Table 2. Effects of SWS suppression on basal and clamp metabolic parameters in 10 healthy controls
Metabolic parameters Normal sleep SwS suppression p-value
Basal values
Glucose (mmol/L) 4.9 ± 0.1 5.0 ± 0.1 0.1
EGP (μmol.kgLBM-1.min-1 ) 19.7 ± 0.8 18.8 ± 0.8 0.3
Clamp conditions
Glucose (mmol/L) 5.9 ± 0.1 6.0 ± 0.1 0.2
Insulin (pmol/L) 148 ± 12 147 ± 9 0.9
EGP (μmol.kgLBM-1.min-1 ) 5.6 ± 0.6 5.1 ± 0.6 0.4
Glucose Rd (μmol.kgLBM-1.min-1 ) 48,6 ± 4.5 45.1 ± 2.8 0.3
Glucose infusion rate (μmol.kgLBM-1.min-1 ) 42.7 ± 4.4 39.7 ± 2.8 0.4
Data are presented as mean ± SEM. SWS, slow wave sleep; EGP, endogenous glucose production; LBM, lean body mass
E f f e c t s  o f  S w S  s u p p r e s s i o n  o n  b a s a l  a n d  i n s u l i n - m e d i a t e d  g l u c o s e 
m e t a b o l i s m
Selective SWS suppression did not alter basal glucose levels nor basal endogenous glucose 
production (EGP), measured the following morning (Table 2). During clamp conditions, 
steady state glucose and insulin levels did not differ between the two occasions. During clamp 
conditions, selective SWS suppression did not result in significant differences in EGP, glucose 
infusion rates or glucose disposal rate. 
D I S C U S S I O N
In the present study, we assessed the effect of a single night of selective SWS suppression on 
insulin sensitivity in healthy controls. We previously showed that a single night of partial sleep 
deprivation induced insulin resistance in healthy subjects and patients with T1DM.(2;12) In those 
studies, duration of total SWS was decreased by ~30% after partial sleep deprivation. The present 
study shows that SWS suppression during a single night did not influence insulin sensitivity, 
assessed by clamp studies, in healthy controls. Therefore, the negative effects of a single night 
of partial sleep restriction are not mediated through a reduction in duration of SWS. 
In the previous study by Tasali et al(4) selective suppression of SWS during multiple subsequent 
nights resulted in impaired glucose metabolism in healthy subjects. However, the design of their 
study differed from the present study in two main aspects. Firstly, SWS was suppressed for three 
consecutive nights versus only for a single night in our study. We cannot exclude the possibility that 
more nights of SWS suppression might provide different results. However, this does not explain why 
a single night of partial restriction of sleep duration already has major impact on insulin sensitivity 
in multiple tissues. Secondly, insulin sensitivity was assessed by an intravenous glucose tolerance 
test (ivGTT) rather than by hyperinsulinemic euglycemic clamp methods, like in our study. As the 
hyperinsulinemic euglycemic clamp method is the most sensitive method for measuring insulin 
sensitivity, it is unlikely that we have missed a major effect of SWS suppression on insulin sensitivity. 
Increased activity of the sympathetic nervous system is associated with insulin resistance.(21) From 
the data obtained by analyses of heart rate variability, we conclude that suppression of SWS sleep did 
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affect the sympathovagal balance. A shift towards sympathetic predominance was observed during 
the night of SWS suppression, in accordance with the observations by Tasali et al.(4) Although we 
measured this increase of relative sympathetic tone during the night of SWS suppression, it might 
be possible that this effect was not maintained during the following morning. In accordance with 
this notion, another study reported no significant changes in daytime HR and HRV after one night 
of selective SWS suppression.(22) Irrespective of the changes in sympathovagal balance during/after 
a night of SWS suppression, this did not affect insulin sensitivity the following morning. Irrespective 
of the results of the current study, our model of a single night of SWS suppression was a valid study 
design, since a single night of partial sleep deprivation induces clear insulin resistance in both 
healthy subjects and DM1 patients.(2;12) Apparently, SWS suppression during a single night does not 
have major effects on insulin sensitivity.
Furthermore, it is well known that inter-individual differences are present in the amount 
of SWS.(23) The mean baseline duration of stage 3 NREM sleep was 111 min for healthy subjects, 
compared to ~80 min in the study by Tasali et al.(4) A possible effect might be explained by the 
difference of absolute duration of remaining SWS sleep. In our study, absolute duration of NREM 
stage 3 sleep after SWS suppression was 30 min longer compared to the data by Tasali et al. Another 
study, designed to assess the effects of sleep continuity disruption, reported a 20 to 25% reduction 
in insulin sensitivity after 2 nights of sleep fragmentation.(24) In that study, micro-arousals were 
induced by acoustic and mechanical stimuli across all sleep stages. Although the total duration of 
SWS was considerably reduced after sleep fragmentation, other sleep stages were also affected, 
including less REM sleep. This argues for a notion that other sleep stages besides SWS play a role 
in reduction of insulin sensitivity of glucose metabolism after interruption of sleep. 
In conclusion, the present study indicates that a night of selective suppression of SWS during 
a single night does not influence insulin sensitivity in healthy subjects. Therefore, the reduction in 
insulin sensitivity by partial sleep deprivation cannot be explained by a reduced duration of SWS. 
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A B S T R A C T
A i m s / h y p o t h e s i s
Decreased sleep duration and/or impaired sleep quality negatively influence glucoregulation. 
The aim of this study was to assess subjective sleep variables in patients with type 1 diabetes, to 
relate sleep parameters to long-term glycaemic control, and to assess possible risk factors for 
impaired sleep. 
M e t h o d s
We studied 99 adult patients with type 1 diabetes (55 men, 44 women, duration of diabetes 
26.9±1.2 yr) and 99 age-, sex-, and BMI- matched non-diabetic controls. Subjective sleep 
characteristics were assessed by validated questionnaires, i.e. Pittsburgh Sleep Quality Index, 
Epworth Sleepiness Scale, and the Berlin Questionnaire. Glucoregulation was assessed by 
HbA
1c
-values. Clinical parameters were obtained from medical charts. Depression was assessed 
by the Hospital Anxiety and Depression Scale (HADS). Peripheral polyneuropathy was assessed 
by neurological examination and quantitative sensory testing.
R e s u l t s
Of the patients with type 1 diabetes, 35% had subjective poor sleep quality compared to 20% 
of the control subjects (P=0.021). A higher proportion of the patients with type 1 diabetes were 
at increased risk for obstructive sleep apnoea (OSA) (17.2% vs. 5.1%, P=0.012). There was no 
significant association between individual sleep characteristics and HbA
1c
-values. On logistic 
regression analysis, the HADS depression score, presence of peripheral polyneuropathy, 
habitual snoring, and other sleep disturbances -e.g. hypoglycaemia- were independently 
associated with poor sleep quality. 
C o n c l u s i o n s / i n t e r p r e t a t i o n
Adult patients with longstanding type 1 diabetes mellitus have disturbed subjective sleep 
quality and a higher risk for OSA, compared to control subjects. Subjective sleep disturbances 
are part of the complex syndrome of longstanding type 1 diabetes.
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I N T R O D U C T I O N
Patients with type 2 diabetes report sleep disturbances more frequently than individuals 
from the general population.(1;2) This is relevant for glucoregulation, as epidemiological(3-5) 
and experimental studies(6-8) have shown that reduced sleep duration and/or decreased sleep 
quality markedly reduce glucose tolerance and insulin sensitivity. 
There are only a few studies on sleep characteristics in patients with type 1 diabetes. Jauch-
Chara et al.(9) reported a trend towards less slow wave sleep in 14 non-hypoglycemic adult 
patients with type 1 diabetes. Children with type 1 diabetes had more disrupted sleep(10;11) and 
more sleep disorders(12) than healthy children. Conversely, in adult patients with type 1 diabetes, 
partial sleep deprivation, even during only a single night, reduced peripheral insulin sensitivity 
by 21%.(13) Subjective sleep characteristics and their relation with glucoregulation have not been 
studied in adult patients with type 1 diabetes.
We hypothesized that adult patients with type 1 diabetes may have alterations in subjective 
sleep characteristics, assessed by validated sleep questionnaires, compared to healthy 
controls. In addition, we hypothesized that subjective sleep disturbances would be associated 
with impaired glucoregulation. Therefore, the aim of the present study was: 1) to assess 
subjective sleep characteristics by validated sleep questionnaires in adult patients with type 1 
diabetes, compared to age-, sex-, and BMI- matched non-diabetic controls, 2) to relate sleep 
characteristics to the quality of glycemic control, i.e. HbA
1c
 values, and 3) to assess possible risk 
factors for impaired sleep in adult patients with type 1 diabetes. 
M E T h O D S
P a r t i c i p a n t s
We included 99 consecutive patients with type 1 diabetes mellitus (55 men, 44 women) 
attending the outpatient clinic of the Leiden University Medical Center, and 99 age-, sex- and 
BMI-matched non-diabetic controls recruited by advertisement. Every patient with type 1 
diabetes was individually matched with one non-diabetic healthy control for age, sex and BMI. 
Exclusion criteria for both groups were 1) previously diagnosed sleep disorders; 2) psychiatric 
disorders and/or use of psychotropic medication; 3) pregnancy or lactation; 4) working in 
nights shifts in the last 3 months; 5) travelling across time zones in the previous month; 6) 
age<18 years; 7) other endocrine disorders; 8) neuropathy caused by other conditions than 
type 1 diabetes; 9) chronic co-morbidity, other than peripheral neuropathy, associated with 
pain; and 10) chronic use of glucocorticoids. The study was approved by the medical ethical 
committee of Leiden University Medical Center, and written informed consent was obtained 
from all subjects prior to the study. 
S t u d y  d e s i g n
Patients and controls were asked to complete 3 validated sleep questionnaires: the Pittsburgh 
Sleep Quality Index (PSQI), Epworth Sleepiness Scale (ESS), and the Berlin Questionnaire 
(BQ), which provide data on sleep quality, daytime sleepiness, and the presence of sleeping 
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disorders.(14-16) An additional questionnaire focused on duration and insulin management of 
type 1 diabetes, use of medication, co-morbidity, current smoking status, and use of alcohol 
and coffee. Four questions aimed to identify restless legs syndrome (RLS), using the minimum 
criteria defined by the International RLS Study group.(17) As depressive feelings may also affect 
sleep characteristics, anxiety and depression scores were assessed by the Hospital Anxiety and 
Depression scale (HADS).(18) Sleep disturbances were identified by the answers of the 10 possible 
encountered sleep disturbances of the PSQI- questionnaire. The option ‘three times or more 
per week’ was taken as the affirmative answer. Habitual snoring was defined as a ‘yes’ answer 
to the 3- item question ‘Do you snore’ in the BQ. The subjects who answered ‘not known’ to 
this question were classified as non-snorers. We also included additional questions: ‘Has your 
sleep been disturbed by hypoglycemia in the past month? Has your sleep been disturbed by 
hyperglycemia in the past month?. The following four options were provided: ‘never’; ‘less 
than once per week’; ‘once or twice per week’; ‘three times or more per week’. The following 
data were obtained from medical records for the 12 months preceding the current study. 
Microvascular complications were defined by the presence of (1) retinopathy identified by 
retinal photography, detailed ophthalmologic examination, and/or previous laser therapy, (2) 
nephropathy identified by increased urinary albumin-to-creatinine ratios (men >2.5 μg/μmol, 
women >3.5 μg/μmol). Macrovascular complications were defined by objective documentation 
of coronary artery disease (diagnostic cardiac exercise test, coronary angiography, documented 
myocardial infarction and/or coronary artery bypass surgery or percutaneous coronary 
interventions), cerebral vascular disease (documented focal neurologic findings supported 
by appropriate imaging studies) or peripheral vascular disease defined by reduced ankle-arm 
index or angiography. Hypertension was defined as systolic blood pressure >135 mmHg or 
diastolic blood pressure >85 mmHg at multiple occasions or treatment with antihypertensive 
medication. All patients had HbA
1c
 data obtained within the previous 3 months. An HbA
1c
 value 
of 7.5% (58 mmol/mol) was taken as cut-off point dividing well controlled versus moderate to 
poorly controlled patients. The presence of peripheral polyneuropathy in the lower extremities 
was assessed by a single researcher (M. van Dijk), both in all type 1 diabetes patients and all 
controls, using the modified Toronto Clinical Neuropathy scale (mTCNs, see below)(19) and a 
neurothesiometer (Scientific laboratory supplies LTD, Notthingham, UK). For the present 
study, peripheral polyneuropathy was considered to be present, using a 2.5% percentile cut-off 
point for abnormality using data from the matched healthy controls of the present study, when 
either mTCNs was >5 points or the vibration perception threshold was > 18.4 Volt (V). 
A s s e s s m e n t  o f  s u b j e c t i v e  s l e e p  c h a r a c t e r i s t i c s 
P i t t s b u r g h  S l e e p  q u a l i t y  i n d e x 
The validated PSQI is a 19-item self-rated questionnaire for assessing subjective sleep quality 
over the previous month. These questions generate seven ‘components’ scores, each weighted 
equally from 0 to 3: subjective sleep quality; sleep duration, habitual sleep efficiency; sleep 
disturbances; use of sleep medication; and daytime dysfunction. The global PSQI score ranges 
from 0 to 21, with higher scores indicating worse sleep quality.(14)
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E p w o r t h  S l e e p i n e s s  S c a l e 
The ESS is a validated 8-item questionnaire, focusing on the likelihood of falling asleep in several 
common situations encountered in daily life on a scale of 0 to 3. Scores ranges from 0 (the least 
sleepy) to 24 (the most sleepy). Scores equal to, or above, 10 are interpreted as hypersomnolence.(15)
B e r l i n  Q u e s t i o n n a i r e  ( B Q )
The BQ consists of 10 questions on risk factors for sleep apnoea, subdivided into three symptom 
categories: 1) snoring and apneas (6 points), 2) wake time sleepiness or fatigue (3 points), 
and 3) the presence of obesity or hypertension (2 points). If two or more categories are positive 
(category 1 and 2: two or more points, category 3: one or more points), a person is at high risk 
of having sleep apnea.(16)
E v a l u a t i o n  o f  d e p r e s s i o n 
H o s p i t a l  A n x i e t y  a n d  D e p r e s s i o n  S c a l e 
The HADS consists of 14 items scoring anxiety and depression. Each item is measured on a 
four-point scale. Score for anxiety and depression subscale range from 0 to 21, and values of 
the total score range from 0 to 42. Higher scores indicate more severe anxiety or depression. A 
total score of 13 or more was considered to be increased.(18) This questionnaire was provided to 
the subjects after the initial study day. Eighty-seven of 99 (78.8%) of the patients and 80 of the 
99 healthy controls (80.8%) returned the HADS questionnaire. The other questionnaires were 
completed by all participating type 1 diabetic patients and controls. 
A s s e s s m e n t  o f  p e r i p h e r a l  p o l y n e u r o p a t h y
M o d i f i e d  To r o n t o  C l i n i c a l  N e u r o p a t h y  s c a l e 
The mTCNs consists of a brief, easily administered semi-structured clinical interview and clinical 
sensory examination to assess symptoms and signs of diabetic sensorimotor polyneuropathy. 
The mTCNS rates individual symptoms (foot pain, numbness, tingling, weakness, imbalance, 
upper limb symptoms) as absent or present, and if present, grades them depending on 
interference with sense of well-being or activities of daily living. Symptoms without interference 
with sense of well-being or activities of daily living are graded as 1, those with interference with 
sense of well-being, but not with activities of daily living as 2, and those which interference 
with both as 3. The clinical sensory examination was performed unilaterally. In case of previous 
trauma the unaffected leg was chosen, and otherwise the choice of the leg was random. 
Pinprick, temperature, light touch, vibration, and position sense were graded as (0) normal; 
(1) abnormal at the toes only; (2) between the toes and the ankle; or (3) above the ankle.(19) For 
each of these modalities, reference stimuli were given to the dorsal site of one hand, after which 
testing was carried out on the sites described before, while subjects kept their eyes closed.
N e u r o t h e s i o m e t e r 
Before testing vibration perception threshold on the toes, subjects were familiarised with vibration 
stimuli by applying these to the dorsum of one hand. Subsequently, vibration stimuli were applied 
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bilaterally to the distal pulp of both toes. Subjects were instructed to indicate when vibration was 
first perceived. Vibration intensity was gradually increased until vibration was first detected by the 
patient or until a maximum output was reached. Testing was carried out with the subject’s eyes 
closed. Testing was carried out twice on each toe, and a mean of both values was calculated in Volts. 
S t a t i s t i c a l  a n a l y s i s
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc.,Chigago, IL, USA). Continuous 
variables were described as mean ± SEM; categorical variables were expressed as proportions. 
We used the paired t test and the McNemar test for differences in means and proportions for 
continuous and categorical paired variables, respectively, and the two-tailed independent t 
test and the X2 test for unpaired data. 
In patients with type 1 diabetes, logistic regression analysis was performed to examine the 
association of each sleep characteristic with poor glycaemic control (yes/no) adjusting for age, sex, 
BMI, use of alcohol (>1 glass/day, yes/no), and anxiety and depression scores according to the HADS. 
To investigate variables for impaired sleep quality (PSQI>5) in the diabetic population, we 
fitted logistic regressions separately for all possible variables that could affect sleep quality: total 
exogenous insulin dose (units per kilogram per day), use of beta-blockers (yes/no), use of ACE-
inhibitors (yes/no), anxiety and depression score according to HADS, presence of hypertension 
(yes/no), nephropathy (yes/no), peripheral polyneuropathy (yes/no), macrovascular disease 
(yes/no), uncomfortable temperatures (yes/no), pain (yes/no), polyuria (yes/no), other sleep 
disturbances (e.g. metabolic dysregulation), habitual snoring (yes/no), high risk for OSA (yes/
no), and RLS (yes/no). In these analyses, we adjusted for the confounders age, gender, and BMI 
by including them as covariates. Subsequently, we performed multivariate logistic regression 
analysis - including age, sex, BMI, HbA
1c
, duration of the diabetes, and the risk factors that 
showed a P- value <0.2 in the preceding separate analyses. 
R E S U L T S
C l i n i c a l  c h a r a c t e r i s t i c s 
We included 99 patients with type 1 diabetes and 99 healthy non-diabetic controls matched for 
gender (55 men, 44 women), age (43.9±1.3 vs. 44.1 ±1.3 yr) and BMI (24.5±0.3 vs. 24.5±0.3 kg/m2). 
The two groups did not differ with respect to current smoking status, use of alcohol and coffee. 
Clinical characteristics are summarized in Table 1. Patients with type 1 diabetes used more 
frequently ACE- inhibitors, calcium antagonists, statins, angiotensin II receptor antagonists and 
anti-platelet agents. According to the HADS, both anxiety (5.0±0.4 vs. 3.7±0.3, p=0.004) and 
depression scores (3.3±0.4 vs.1.6±0.2, p=0.001) were significantly higher in the patients with 
type 1 diabetes. Thirteen patients (13.1%) had elevated scores for anxiety and depression (total 
HADS score 13 or more) vs. 6 (6.1%) of the controls (p=0.267).The mean duration of the diabetes 
was 26.9±1.2 yr. HbA1c values were 7.8±0.1% (32±13 mmol/mol). Multiple daily insulin injections 
were used by 85 patients and the other 14 patients used continuous s.c. insulin infusion. The 
mean insulin dose was 0.70±0.0 EH kg-1day-1. Microvascular complications were present in 
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Table 1. Clinical characteristics of the patients with type 1 diabetes and their non-diabetic matched controls.





Male/female 55/ 44 55/ 44 1.000
Age (years) 43.9±1.3 44.1 ±1.3 0.472
BMI (kg/m2) 24.5±0.3 24.5±0.3 0.986
BMI>30 kg/m2 4 (4.0) 6 (6.1) 0.727
HbA1c, %/ mmol/mol 7.8±0.1/62±1.3 NA
HbA1c > 7.5% (> 58 mmol/mol) 48 (48.5)
Duration of diabetes (years) 26.9±1.2 NA
Mean insulin dose (U kg-1day-1) 0.7±0.0 NA
Medications, n (%)
Insulin NA
Continuous subcutaneous insulin infusion 14 (14.0)
Insulin injections 85 (86.0)
Beta-blockers 6 (6.1) 4 (4.0) 0.754
ACE-inhibitors 29 (29.3) 5 (5.1) 0.000
Calcium antagonists 9 (9.1) 2 (2.0) 0.039
Statins 39 (39.4) 6 (6.1) 0.000
Oral antidiabetics 1 (1.0) 0 1.000
Angiotensine II receptor antagonists 9 (9.1) 1 (1.0) 0.021
Diuretics 8 (8.1) 3 (3.0) 0.227
Oral anticontraceptives 7 (7.1) 8(8.1) 1.000
Antiplatelet agents 17 (17.2) 2 (2.0) 0.000
Proton pump inhibitors 6 (6.1) 2 (2.0) 0.289
Benzodiazepines 0 0
Other 24 (24.2) 18 (18.2) 0.391
Diabetic complications, n (%) NA
Microvascular: 36 (36.4)
Retinopathy 24 (24.2)
Laser treatment 18 (18.2)
Nephropathy 19 (19.2)
Macrovascular 15 (15.0)
Peripheral polyneuropathy 45 (45.5) 2 (2.0) 0.000
mTCNs-score 5.6±0.5 1.4±0.2 0.000
Neurothesiometer (Volt) 11.5±0.9 6.8±0.4 0.000
Hypertension, n (%) 24 (22.0)
Current cigarette smokers, n (%) 18 (18.0) 11 (11.0) 0.210
Alcohol consumption > 1 glass/day, n (%) 41 (41.4) 36 (36.4) 0.551
Coffee consumption > 1 cup/day, n (%) 75 (75.8) 79(79.8) 0.307
Hospital Anxiety and Depression score (HADS)
Anxiety score 5.0±0.4 3.7±0.3 0.004
Depression score 3.3±0.4 1.6±0.2 0.001
Total score 8.3±0.7 5.3±0.5 0.002
Score > 13 13 (13.1) 6 (6.1) 0.267
Data are mean ± SEM for continuous variables and n (%) for categorical variables; mTCNs=modified Toronto 
Clinical Neuropathy scale; NA= not applicable
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36 patients: 24 patients had retinopathy, and 19 patients had nephropathy. The criteria for 
peripheral polyneuropathy were met by 45 patients compared with two of the matched healthy 
controls (p=0.000). Peripheral polyneuropathy was considered to be present, using a 2.5% 
percentile cut-off point for abnormality using data from the matched healthy controls of the 
present study, when either mTCNs was >5 points or the vibration perception threshold was >18.4 
V. Macrovascular complications were present in 15 patients. 
S u b j e c t i v e  s l e e p  c h a r a c t e r i s t i c s 
Self-reported mean duration of sleep in the PSQI did not differ between patients and controls 
(7.2±0.1 vs. 7.1±0.1 hr, p=0.372; Table 2). In addition, the proportion of short sleepers (< 5 hr) did 
not differ significantly between the 2 groups (1 vs. 1%, p=1.00), and nor did the proportion of 
long sleepers (>9 hr: 1 vs. 1%, p=1.00). Although there were no significant differences in global 
PSQI scores between patients and controls, 35.4% of the patients had a total PSQI score >5, 
compared to only 19.2% of the controls, indicating a higher number of patients with poor 
sleep quality (p=0.021). In the individual domains of the PSQI questionnaire, patients more 
often reported sleep disturbances (p=0.001) and daytime dysfunction (p=0.031). The following 
Table 2. Subjective sleep characteristics of the patients with type 1 diabetes vs. matched non-diabetic controls. 





Self-reported sleep duration, hr 7.2±0.1 7.1 ±0.1 0.372
Sleep quality
Pittsburgh Sleep Quality Index (PSQI) 
Global score 4.6±0.3 4.0±0.2 0.079
PSQI > 5, n (%) 36 (35.4) 20 (19.2) 0.021
PSQI Component-score
1. Subjective sleep quality 0.88 ± 0.1 0.73 ± 0.1 0.096
2. Sleep latency 0.68 ± 0.1 0.74 ± 0.1 0.598
3. Sleep duration 0.73 ± 0.1 0.77 ± 0.1 0.781
4. Sleep efficiency 0.31 ± 0.1 0.22 ± 0.1 0.307
5. Sleep disturbances 1.12 ± 0.0 0.92 ± 0.0 0.001
6. Sleeping medication 0.13 ± 0.0 0.06 ± 0.0 0.239
7. Daytime dysfunction 0.75 ± 0.1 0.52 ± 0.1 0.031
Daytime sleepiness
Epworth Sleepiness scale (ESS)
Total score 5.9 ±0.4 5.1 ± 0.4 0.192
Score >10, n(%) 19 (19.2) 11(11.1) 0.152
Sleep disorders, n (%)
Berlin Questionnaire (BQ)
Habitual snoring 51 (51.0) 34 (34.0) 0.010
High risk OSA 17 (17.2) 5 (5.1) 0.012
Restless legs syndrome (RLS) 9 (9.3) 10 (10.1) 1.000
Data are mean ± SEM for continuous variables and n (%) for categorical variables. OSA= obstructive sleep apnoea
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sleep disturbances occurred more often in patients than in controls: polyuria (42.4 vs. 24.2%, 
p=0.004); pain (8.1% vs. 0%, p=0.008); uncomfortable temperatures (8.1% vs. 1.0%, p=0.021); and 
habitual snoring(51% % vs. 34%, p=0.010). The BQ indicated that more patients were at high risk 
for obstructive sleep apnoea (OSA) than controls (17.2 vs. 5.1%, p=0.012). Despite the reduction in 
sleep quality and more sleep disorders, there were no significant differences in reported daytime 
sleepiness between the 2 groups. Daytime hypersomnolence affected 19.2% of the patients 
versus 11.1% of the controls (p=0.152). Seventy-five patients answered the questions: ’Has your 
sleep been disturbed by hypoglycaemia in the past month? Has your sleep been disturbed by 
hyperglycaemia in the past month?’ Forty-one patients indicated that their sleep was disturbed 
by hypoglycaemia in the past month; 34 patients indicated that their sleep was disturbed less 
than once per week, and 7 patients indicated impaired sleep by hypoglycaemia 1-2 times per 
week. Disturbed sleep due to hyperglycaemia was reported by 28 patients with type 1 diabetes; 
24 patients indicated disturbed sleep less than once per week, 2 patients 1-2 times per week, and 
2 patients reported a disturbed sleep by hyperglycaemia more than 3 times per week. 
we l l  c o n t r o l l e d  v s .  m o d e r a t e  t o  p o o r l y  c o n t r o l l e d  p a t i e n t s 
Type 1 diabetes patients were divided in two groups: well controlled (HbA1c<7.5 % [<58 mmol/
mol], n=51) vs. moderate to poorly controlled (HbA1c>7.5% [> 58 mmol/mol], n=48). There were 
no significant differences in clinical characteristics between both groups. We found no significant 
differences between both groups in subjective sleep characteristics, i.e. self-reported sleep 
duration, sleep quality, daytime sleepiness, or the prevalence of sleep disorders (data not shown). 
Logistic regression analysis was performed to assess the association between self-reported 
sleep characteristics and high HbA1c values (>7.5% [> 58 mmol/mol]). There were no significant 
associations between individual sleep characteristics and impaired glycaemic control (Table 3).
A s s e s s m e n t  o f  r i s k  f a c t o r s  o f  i m p a i r e d  s l e e p  q u a l i t y  ( P S Q I > 5 )  
i n  p a t i e n t s  w i t h  t y p e  1  d i a b e t e s 
Logistic regression analyses for all possible variables that could affect sleep quality in patients 
with type 1 diabetes showed significant associations between impaired sleep quality and the 
presence of peripheral polyneuropathy (OR 2.98, 95% CI 1.05-8.46, p=0.040), habitual snoring 
(OR 4.19, 95% CI 1.47-11.97, p=0.007), uncomfortable temperatures (OR 7.89, 95% CI 1.31-47.31, 
p=0.024), other sleep disturbances, e.g. metabolic dysregulation (OR 9.52, 95% CI 1.03-88.17, 
p=0.047), HADS anxiety score (OR 1.20, 95% CI 1.02-1.40, p=0.026), and HADS depression score 
(OR 1.30, 95% CI 1.07-1.58, p=0.009; Table 4). 
Multivariate logistic regression, including age, sex, BMI, HbA
1c , 
duration of the diabetes and 
the risk factors, that showed a p value <0.2 in the preceding separate analyses confirmed that 
habitual snoring (OR 9.95, 95% CI 1.76-56.14, p=0.009), HADS depression score (OR 1.42,95% 
CI 1.00-2.02, p = 0.048), presence of peripheral polyneuropathy (OR 7.45, 95% CI 1.08-51.20, 
p =0.041) and other sleep disturbances (e.g.metabolic dysregulation (OR 27.78, 95% CI 1.11-
697.48, p=0.043) were still independent risk factors for poor sleep in type 1 diabetes. Peripheral 
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Table 3. Results of logistic regression analysis of the association between sleep characteristics and impaired 
glucoregulation in 99 patients with type 1 diabetes.
hbA1c> 7.5% (>58 mmol/mol)
Odds Ratio (95% CI) P-value
Sleep duration*
Self- reported sleep duration ( hr) 0.77 (0.48-1.24) 0.287
Sleep quality*
PSQI
Global PSQI-score 1.06 (0.89-1.27) 0.532
PSQI>5 1.31 (0.47-3.63) 0.602
Daytime sleepiness*
ESS
Total ESS-score 1.04 (0.92-1.18) 0.521
ESS>10 2.82 (0.84-9.42) 0.093
Sleep disorders 
BQ
Habitual snoring 1.24 (0.51-3.01) 0.639
High risk obstructive sleep apnea (OSA) 0.50 (0.15-1.59) 0.238
RLS 2.59 (0.59-11.41) 0.209
Each sleep characteristic was adjusted for age, gender, BMI, and alcohol consumption (> 1 glass/day). *Also 
adjusted for HADS.
polyneuropathy, clinically assessed according to strict criteria, was an independent risk factor 
for impaired sleep, even after adjusting for ‘pain’ and ‘uncomfortable temperatures’. 
D I S C U S S I O N 
The aim of this study was to assess subjective sleep characteristics in adult patients with 
longstanding type 1 diabetes, and to relate sleep parameters to HbA
1c
 values. Although sleep 
duration did not differ between patients and controls, more patients had poor sleep quality 
compared to non-diabetic, age-, gender, and BMI-matched controls. Patients with type 1 
diabetes reported more sleep disturbances and daytime dysfunction. A higher proportion 
of the patients with type 1 diabetes were at increased risk for OSA. There was no association 
between subjective sleep characteristics and impaired glucoregulation. These observations 
indicate that type 1 diabetes is associated with an increased prevalence of disturbed subjective 
sleep characteristics, which do not relate to glucoregulation. 
Previous studies on the relation between diabetes and sleep characteristics mainly focussed 
on patients with type 2 diabetes.(1;2) Only a few studies have assessed sleep characteristics 
in patients with type 1 diabetes.(9-12) Those studies investigated relatively few subjects and 
children(10-12) with type 1 diabetes. The present study extends those observations in showing 
that in a large group of adult patients with a long history of type 1 diabetes subjective sleep 
characteristics are impaired, compared to a carefully matched control group, controlling for 
potential confounding factors like age, sex and BMI.
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Table 4. Results of logistic regression: possible risk factors for impaired sleep quality (PSQI>5) in 99 patients 
with type 1 diabetes
Characteristic
Poor sleep quality (PSQI>5)
minimally adjusted maximally adjusted
(adjusted for age, sex, and BMI)
OR (95% CI) P-value OR (95% CI) P-value
Clinical characteristics
Use of medication
Total insulin dose (EHk-1 day-1) 1.32 (0.21-8.31) 0.768 NI
Use of beta-blockers 1.00 (0.17-5.92) 0.996 NI
Use of ACE-inhibitors 0.42 (0.14-1.25) 0.118 0.85 (0.14-5.11) 0.859
Anxiety and depressive symptoms 
HADS Anxiety 1.20 (1.02-1.40) 0.026 0.91 (0.66-1.26) 0.572
HADS Depression 1.30 (1.07-1.58) 0.009 1.42 (1.00-2.02) 0.048
Diabetic complications 
Hypertension 0.41 (0.13-1.31) 0.133 0.38 (0.06-2.32) 0.292
Presence of nephropathy 0.88 (0.29-2.68) 0.828 *
Macrovascular disease 0.78 (0.21-2.92) 0.707 *
Presence of peripheral neuropathy 3.0 (1.05-8.46) 0.040 7.45 (1.08-51.20) 0.041
Sleep disturbances
Uncomfortable temperatures 7.89 (1.31-47.31) 0.024 4.30 (0.27-69.45) 0.304
Presence of pain 3.38 (0.72-15.84) 0.122 6.50 (0.50-
84.43)
0.152
Polyuria 1.49 (0.20-3.97) 0.405 *
Other sleep disturbances, e.g. 
metabolic dysregulation
9.52 (1.03-88.17) 0.047 27.78(1.11-697.4) 0.043
Sleep disorders
Habitual snoring 4.20 (1.47-11.97) 0.007 9.95 (1.76-56.14) 0.009
High risk OSA 1.27 (0.40-4.05) 0.682 *
Restless legs syndrome 0.89 (0.20-3.97) 0.883 *
HADS=Hospital Anxiety and Depression scale; OR=odds ratio; NI=Not included in final model because of P-value > 0.2
This decrease in sleep quality and increased prevalence of sleep disturbances in patients 
with longstanding type 1 diabetes may have important implications, since previous studies 
showed that reduction of sleep duration and/or decreased sleep quality impair glucose 
tolerance and reduce insulin sensitivity in healthy controls.(6-8) Sleep disturbances might have 
a similar negative effect on glucose metabolism in patients with type 1 diabetes, resulting in 
worse diabetic control. However, this presumed relationship between sleep disturbances and 
impaired glucose metabolism, assessed by HbA
1c
 values, was not detectable in the current 
study. Nonetheless, it is still possible that disturbed sleep characteristics influence glucose 
metabolism in these patients. However, the effects of impaired sleep characteristics may 
not simply be reflected in HbA
1c
 values, because intensive glucose control and frequent, 
appropriate adjustments of insulin doses in patients at risk might have obtunded the effects 
of impaired sleep characteristics on glucoregulation. Various aspects of diabetes could be 
linked to disturbed sleep quality, including physical complications of the disease, psychological 
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factors, metabolic fluctuations, and high prevalence of sleep disorders. In the patients with 
type 1 diabetes in our study, disturbed sleep quality was independently associated with 
habitual snoring, higher depression scores according to the HADS questionnaire, presence of 
polyneuropathy, and other sleep disturbances, mainly by hypoglycaemia. 
Previous studies showed a high prevalence of depression in diabetes(20) and chronic pain 
conditions.(21) Although we excluded patients with a known depression, use of psychotropic 
drugs, and co-morbid disorders (other than neuropathy) associated with pain, in our study 
higher depression scores are independently associated with impaired sleep quality. Many 
patients with type 1 diabetes in our study used ACE-inhibitors, statins, and/or beta-blockers 
which might interfere with sleep characteristics. The effects of beta-blockers on sleep are not 
equivocal. A previous study showed that the use of beta-blockers could positively or negatively 
affect sleep.(22) A case-report by Cicolin et al. suggested that ACE-inhibitors may contribute to 
OSA by inducing upper airway inflammation.(23) Therefore, we have considered that the use of 
beta-blockers and/or ACE-inhibitors might affect sleep quality in patients with type 1 diabetes. 
However, in univariate logistic regression analysis we did not find an association between the use 
of beta-blockers and impaired sleep quality and between the use of ACE-inhibitors and impaired 
sleep quality. In univariate logistic regression analysis there was an association between the use 
of ACE-inhibitors and high risk of OSA. However, this association was no longer significant after 
correction for the confounders age, sex, BMI and hypertension. There are conflicting data on 
sleep disturbances in patients treated with statins. Some studies reported higher prevalence of 
sleep disturbances in patients treated with lipophilic statins than with pravastatin(24;25) whereas 
other studies did not find an increased prevalence of sleep disturbances in patients treated with 
different statins compared to placebo.(26;27) In the present study, there was no difference in the 
use of statins between patients with a poor sleep quality (PSQI > 5) and patients with a good 
sleep quality (PSQI <5). The use of statins was even higher in the group with good sleep quality. In 
accordance, in univariate analysis, use of statins was not associated with impaired sleep quality. 
Therefore, our conclusions are not likely to be merely explained by the use of medications in 
our patients. The clinical assessment of peripheral polyneuropathy according to strict criteria 
in subjects with type 1 diabetes is a major strength of our study, since our study shows diabetic 
polyneuropathy was a major determinant of impaired sleep. Polyneuropathy contributes to 
impaired sleep via several potential mechanisms. First, neuropathic pain may lead to disturbed 
sleep.(28) Second, polyneuropathy can impair thermoregulation. It has been proposed that 
autonomic changes in skin temperature modulate the neuronal activity of the thermosensitive 
neurons in the preoptic area/ anterior hypothalamus, which in turn regulate vigilance and 
sleepiness.(29) This hypothesis is supported by a report showing that diabetic patients, even those 
without evidence of clinical neuropathy, showed impaired thermoregulation during sleep.(30)
The relatively high prevalence of type 1 diabetic patients with a high risk for OSA, according 
the Berlin Questionnaire (BQ), suggests the potential of a high burden of unrecognised OSA in 
people with type 1 diabetes. This is a relatively new finding, in accordance with a recent pilot 
study of Borel et al., which observed a prevalence of OSA of 40% in 37 non-obese adult patients 
with type 1 diabetes.(31) In accordance with our data, this observation is remarkable, since BMI, 
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which is a risk factor for OSA in the general population, of our patients with type 1 diabetes 
was matched to that of the healthy controls. Several studies in patients with type 2 diabetes 
have shown that OSA is associated with the presence of autonomic neuropathy(32;33), which 
might also be involved in patients with type 1 diabetes. Unfortunately, our current study was 
not designed to elucidate underlying mechanisms of disturbed sleep, and we did not include 
assessments of autonomic neuropathy. Nonetheless, there was no association between poor 
glycaemic control (HbA1c>7.5% [> 58 mmol/mol]) and a ‘high’ risk for OSA in our study, despite 
the association between sleep disordered breathing, glucose intolerance and insulin resistance 
in patients with type 2 diabetes.(34;35) There was also no association between the occurrence of 
hypoglycemias and the risk for OSA in our patients.(36) 
Sleep characteristics were assessed by validated questionnaires in the present study. The 
PSQI and the ESS have been developed to measure sleep quality and daytime sleepiness, 
respectively(14;15), and reflect stable measures of sleep quality and sleepiness over the past 
year.(37) The PSQI has a diagnostic sensitivity 89.6% and specificity of 86.5% for identifying cases 
with poor sleep quality, using a cut-off score of 5. This questionnaire has been validated by 
polysomnographic measurements.(38) The BQ is a widely used screening tool to differentiate 
between ‘high’ and ‘low’ risk groups for OSA. This risk grouping was useful in the prediction 
of respiratory disturbances in consecutive participants, who visited internists for any reason. 
For example, being in the ‘high-risk’ group defined by the BQ, predicted more than respiratory 
events per hour with a sensitivity of 86%, and a specificity of 77%.(16) In view of the current data, 
polysomnography is required to objectively assess the sleep quality and OSA in patients with type 
1 diabetes mellitus at high risk for OSA according to the BQ. The current cross-sectional study 
was designed to assess subjective sleep parameters in patients with type 1 diabetes mellitus and, 
therefore, we cannot elucidate from the data which chain(s) of events lead from type 1 diabetes 
to disturbed sleep. In particular, the links between peripheral polyneuropathy and disturbed 
sleep and between type 1 diabetes and the risk of OSA are not fully clear. Another matter is 
whether disturbed sleep leads to further impairment of glucose metabolism, with the effect that 
sleep disturbances and glycaemic control can interact in a vicious circle. Additional studies with 
objective sleep measurements are warranted to assess these relations in more detail. 
In conclusion, the present study demonstrated that adult patients with longstanding type 
1 diabetes mellitus have altered self-reported sleep characteristics compared to gender-, age- 
and BMI matched non-diabetic controls. Therefore, disturbed subjective sleep characteristics 
are part of the complex syndrome of longstanding type 1 diabetes mellitus. 
67
5
R E F E R E N C E  L I S T
1 Skomro RP, Ludwig S, Salamon E, Kryger MH. Sleep 
complaints and restless legs syndrome in adult 
type 2 diabetics. Sleep Med 2001; 2(5):417-422.
2 Resnick HE, Redline S, Shahar E et al. Diabetes and 
sleep disturbances: findings from the Sleep Heart 
Health Study. Diabetes Care 2003; 26(3):702-709.
3 Gottlieb DJ, Punjabi NM, Newman AB et al. 
Association of sleep time with diabetes mellitus 
and impaired glucose tolerance. Arch Intern Med 
2005; 165(8):863-867.
4 Ayas NT, White DP, Al-Delaimy WK et al. A 
prospective study of self-reported sleep duration 
and incident diabetes in women. Diabetes Care 
2003; 26(2):380-384.
5 Yaggi HK, Araujo AB, McKinlay JB. Sleep duration 
as a risk factor for the development of type 2 
diabetes. Diabetes Care 2006; 29(3):657-661.
6 Spiegel K, Leproult R, Van CE. Impact of sleep debt 
on metabolic and endocrine function. Lancet 
1999; 354(9188):1435-1439.
7 Donga E, van DM, van Dijk JG et al. A Single 
Night of Partial Sleep Deprivation Induces Insulin 
Resistance in Multiple Metabolic Pathways in 
Healthy Subjects. J Clin Endocrinol Metab 2010.
8 Tasali E, Leproult R, Ehrmann DA, Van CE. Slow-
wave sleep and the risk of type 2 diabetes 
in humans. Proc Natl Acad Sci U S A 2008; 
105(3):1044-1049.
9 Jauch-Chara K, Schmid SM, Hallschmid M, Born 
J, Schultes B. Altered neuroendocrine sleep 
architecture in patients with type 1 diabetes. 
Diabetes Care 2008; 31(6):1183-1188.
10 Happe S, Treptau N, Ziegler R, Harms E. Restless 
legs syndrome and sleep problems in children 
and adolescents with insulin-dependent diabetes 
mellitus type 1. Neuropediatrics 2005; 36(2):98-103.
11 Matyka KA, Crawford C, Wiggs L, Dunger DB, 
Stores G. Alterations in sleep physiology in 
young children with insulin-dependent diabetes 
mellitus: relationship to nocturnal hypoglycemia. 
J Pediatr 2000; 137(2):233-238.
12 Villa MP, Multari G, Montesano M et al. Sleep apnoea 
in children with diabetes mellitus: effect of glycaemic 
control. Diabetologia 2000; 43(6):696-702.
13 Donga E, van DM, van Dijk JG et al. Partial sleep 
restriction decreases insulin sensitivity in type 1 
diabetes. Diabetes Care 2010.
14 Buysse DJ, Reynolds CF, III, Monk TH, Berman SR, 
Kupfer DJ. The Pittsburgh Sleep Quality Index: 
a new instrument for psychiatric practice and 
research. Psychiatry Res 1989; 28(2):193-213.
15 Johns MW. A new method for measuring daytime 
sleepiness: the Epworth sleepiness scale. Sleep 
1991; 14(6):540-545.
16 Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl 
KP. Using the Berlin Questionnaire to identify 
patients at risk for the sleep apnea syndrome. Ann 
Intern Med 1999; 131(7):485-491.
17 Allen RP, Picchietti D, Hening WA, Trenkwalder C, 
Walters AS, Montplaisi J. Restless legs syndrome: 
diagnostic criteria, special considerations, and 
epidemiology. A report from the restless legs 
syndrome diagnosis and epidemiology workshop 
at the National Institutes of Health. Sleep Med 
2003; 4(2):101-119.
18 Zigmond AS, Snaith RP. The hospital anxiety and 
depression scale. Acta Psychiatr Scand 1983; 
67(6):361-370.
19 Bril V, Tomioka S, Buchanan RA, Perkins BA. 
Reliability and validity of the modified Toronto 
Clinical Neuropathy Score in diabetic sensorimotor 
polyneuropathy. Diabet Med 2009; 26(3):240-246.
20 Anderson RJ, Freedland KE, Clouse RE, Lustman 
PJ. The prevalence of comorbid depression in 
adults with diabetes: a meta-analysis. Diabetes 
Care 2001; 24(6):1069-1078.
21 Gore M, Brandenburg NA, Dukes E, Hoffman DL, 
Tai KS, Stacey B. Pain severity in diabetic peripheral 
neuropathy is associated with patient functioning, 
symptom levels of anxiety and depression, and 
sleep. J Pain Symptom Manage 2005; 30(4):374-385.
22 Yilmaz MB, Erdem A, Yalta K, Turgut OO, Yilmaz 
A, Tandogan I. Impact of beta-blockers on sleep 
in patients with mild hypertension: a randomized 
trial between nebivolol and metoprolol. Adv Ther 
2008; 25(9):871-883.
23 Cicolin A, Mangiardi L, Mutani R, Bucca C. 
Angiotensin-converting enzyme inhibitors and 
obstructive sleep apnea. Mayo Clin Proc 2006; 
81(1):53-55.
24 Golomb BA, Kwon EK CMDJ. Abstract 3725: 
Simvastatin but not pravastatin affects sleep: 
Findings from the UCSD Statin Study. Circulation 
116, II_847. 2011. Ref Type: Abstract
25 Vgontzas AN, Kales A, Bixler EO, Manfredi RL, 
Tyson KL. Effects of lovastatin and pravastatin on 
sleep efficiency and sleep stages. Clin Pharmacol 
Ther 1991; 50(6):730-737.
26 Eckernas SA, Roos BE, Kvidal P et al. The effects 
of simvastatin and pravastatin on objective 
and subjective measures of nocturnal sleep: a 
comparison of two structurally different HMG 
68
5
CoA reductase inhibitors in patients with primary 
moderate hypercholesterolaemia. Br J Clin 
Pharmacol 1993; 35(3):284-289.
27 Ehrenberg BL, Lamon-Fava S, Corbett KE, 
McNamara JR, Dallal GE, Schaefer EJ. Comparison 
of the effects of pravastatin and lovastatin on sleep 
disturbance in hypercholesterolemic subjects. 
Sleep 1999; 22(1):117-121.
28 Zelman DC, Brandenburg NA, Gore M. Sleep 
impairment in patients with painful diabetic 
peripheral neuropathy. Clin J Pain 2006; 22(8):681-
685.
29 Raymann RJ, Swaab DF, Van Someren EJ. Skin deep: 
enhanced sleep depth by cutaneous temperature 
manipulation. Brain 2008; 131(Pt 2):500-513.
30 Rutkove SB, Veves A, Mitsa T et al. Impaired 
distal thermoregulation in diabetes and diabetic 
polyneuropathy. Diabetes Care 2009; 32(4):671-676.
31 Borel AL, Benhamou PY, Baguet JP et al. High 
prevalence of obstructive sleep apnoea syndrome 
in a Type 1 diabetic adult population: a pilot study. 
Diabet Med 2010; 27(11):1328-1329.
32 Ficker JH, Dertinger SH, Siegfried W et al. 
Obstructive sleep apnoea and diabetes mellitus: 
the role of cardiovascular autonomic neuropathy. 
Eur Respir J 1998; 11(1):14-19.
33 Bottini P, Dottorini ML, Cristina CM, Casucci 
G, Tantucci C. Sleep-disordered breathing in 
nonobese diabetic subjects with autonomic 
neuropathy. Eur Respir J 2003; 22(4):654-660.
34 Harsch IA, Schahin SP, Bruckner K et al. The effect 
of continuous positive airway pressure treatment 
on insulin sensitivity in patients with obstructive 
sleep apnoea syndrome and type 2 diabetes. 
Respiration 2004; 71(3):252-259.
35 Punjabi NM, Shahar E, Redline S, Gottlieb DJ, 
Givelber R, Resnick HE. Sleep-disordered 
breathing, glucose intolerance, and insulin 
resistance: the Sleep Heart Health Study. Am J 
Epidemiol 2004; 160(6):521-530.
36 Paranjape SA, Vavaiya KK, Kale AY, Briski KP. 
Habituation of insulin-induced hypoglycemic 
transcription activation of lateral hypothalamic 
orexin-A-containing neurons to recurring 
exposure. Regul Pept 2006; 135(1-2):1-6.
37 Knutson KL, Rathouz PJ, Yan LL, Liu K, Lauderdale 
DS. Stability of the Pittsburgh Sleep Quality Index 
and the Epworth Sleepiness Questionnaires over 
1 year in early middle-aged adults: the CARDIA 
study. Sleep 2006; 29(11):1503-1506.
38 Buysse DJ, Reynolds CF, III, Monk TH, Hoch CC, 
Yeager AL, Kupfer DJ. Quantification of subjective 
sleep quality in healthy elderly men and women 





C O N T R O L L E D  h Y P E R G L Y C E M I C 
D Y S R E G U L A T I O N  D O E S  N O T 
S I G N I F I C A N T L Y  A F F E C T  O B j E C T I V E 
S L E E P  C h A R A C T E R I S T I C S  I N  P A T I E N T S 
w I T h  T Y P E  1  D I A B E T E S
Marieke van Dijk, Esther Donga, J Gert van Dijk, Jitske Tiemensma, 
Klaas W. van Kralingen, Petronella H. Geelhoed-Duijvestijn, 
Eleonora PM Corssmit, Johannes A Romijn
Submitted
6
A B S T R A C T
O b j e c t i v e
Sleep restriction decreases insulin sensitivity in patients with type 1 diabetes, leading to 
hyperglycemia. We hypothesized that hyperglycemia might conversely impair sleep in well-
controlled patients with type 1 diabetes on stable continuous subcutaneous insulin infusion 
therapy (CSII).
R e s e a r c h  d e s i g n  a n d  m e t h o d s
We studied 7 well-controlled patients with type 1 diabetes on stable CSII on two occasions: 
once during a normoglycemic night and their habitual doses of insulin and once during a night 
of controlled hyperglycemia caused by reduction of the insulin infusion rates by 50%. Sleep 
characteristics were assessed by polysomnography. 
R e s u l t s
Reduction in insulin infusion rates increased plasma glucose by ~250% (6.5±0.6 vs.16.0±0.6 
mmol/l, p=<0.001). This did not significantly affect objective sleep characteristics, i.e. sleep 
duration, quality, latency, efficiency and the apnea-hypopnea index.
C o n c l u s i o n s
Reduction of insulin availability, resulting in hyperglycemic dysregulation, does not have 
significant effects on objective sleep characteristics in patients with type 1 diabetes. 
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I N T R O D U C T I O N
Patients with type 1 diabetes tend to have less slow wave sleep and more stadium 2 non-REM (NREM) 
sleep (1;2), impaired sleep quality and more frequent obstructive sleep apnea(3) compared with healthy 
non-diabetic controls. This is most likely related to complex interactions between metabolic control, 
physical complications, psychological factors, and high prevalence of sleep disorders.(2-4)
The alterations in sleep characteristics are relevant for metabolic regulation, since, for 
instance, sleep duration is a determinant of insulin sensitivity in these patients.(5) Conversely, 
it is possible that hyperglycemic dysregulation, which is frequently present in these patients, 
might affect sleep characteristics. This might, in turn, impair glucose tolerance and insulin 
sensitivity, creating a vicious circle. 
We hypothesized that a night of hyperglycemic dysregulation through reduction of insulin 
administration impairs sleep characteristics in adult patients with type 1 diabetes. 
Therefore, the aim of the present study was to compare the effects of a night of controlled 
hyperglycemia, by reduction of the basal and bolus insulin infusion rates by 50%, versus a night 
of normoglycemia during habitual insulin administration on objective sleep characteristics in 
well-controlled patients with type 1 diabetes. 
S T U D Y  D E S I G N  A N D  M E T h O D S 
P a t i e n t s
We included 7 well-controlled patients (4 men) with type 1 diabetes on stable continuous 
subcutaneous insulin pump therapy (CSII). Diagnostic criteria for type 1 diabetes were past 
or present positive antibodies against GAD or islet cells and plasma free C-peptide levels 
<0.3 nmol/l. All participants were screened at our outpatient clinic prior to the study. Exclusion 
criteria were: 1) age <18 or > 65 yr; 2) previously diagnosed sleep disorders, or abnormal scores 
in one of three validated sleep questionnaires (Pittsburgh Sleep Quality Index(6), Epworth 
Sleepiness Scale(7), and Berlin Questionnaire(8)); 3) night shift work in the month before the 
study nights; 4) travelling across time zones in the previous month; 5) psychiatric disorders 
and/or use of psychotropic medication, or high total score, i.e. >13, on the Hospital Anxiety 
and Depression Scale (HADS) (9) since depression is known to have an impact on sleep 
and cognitive performance; 6) chronic use of sleep medication and/or melatonin; 7) other 
endocrine diseases; 8) pregnancy or lactation; 9) clinical signs of (autonomic) neuropathy; 10) 
(chronic) co- morbidity associated with pain; 11) HbA
1c
>8% in the year prior to the study. The 
study was approved by the medical ethical committee of Leiden University Medical Center and 
written informed consent was obtained from all patients prior to the study. 
S t u d y  d e s i g n
Patients were studied on two days, separated by at least three weeks. They were asked to 
maintain a standardized schedule of meals and bedtimes the week before a study night and not 
to alter the insulin regimes during the study days. Self-reported sleep duration and quality were 
assessed using the Pittsburgh Sleep Quality Index.(6) History of glucoregulation was obtained 
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from medical records and an additional questionnaire focusing on glycemic history. One or 
two days before each study day, a continuous glucose monitoring system (CGMS) sensor was 
inserted. Patients were admitted to our hospital the afternoon preceding each study night and 
spent 8.5 hr in bed from 11.00 PM to 7.30 AM the next morning on both occasions. The sequence 
of the euglycemic and hyperglycemic occasions were randomly assigned. The numbers of 
toilet visits during the nights were noted. 
During the study day of hyperglycemia, patients were called at 8.00 AM by a research 
physician to reduce their basal and bolus insulin infusions with 50% during 24 hr aimed to 
obtain and maintain hyperglycemia with glucose levels between 15-20 mmol/L. Patients were 
instructed to check blood glucose levels at least four times a day. If it was >= 20 mmol/L or if 
they had complaints of hyperglycemia, they were instructed to consult one of the researchers 
(M. van Dijk) to adjust their insulin dose to prevent further increase of blood glucose levels. The 
patients were able to reach the research physician by telephone 24 hr/day. 
A s s e s s m e n t  o f  g l u c o r e g u l a t i o n
C o n t i n u o u s  g l u c o s e  m o n i t o r i n g  s y s t e m  (C G M S )
Each patient wore a CGMS (Medtronic Minimed iPRO-2, Northridge, CA, US) uninterruptedly 
for two or three days in order to obtain reliable blood glucose values during study nights and to 
document daily blood glucose fluctuations. The CGMS sensor was inserted into the abdominal 
area and provided a measurement of interstitial tissue fluid glucose once every 5 min. 
Counseling on sensors was given at the initial visit when the sensor was placed. While wearing 
the CGMS patients had to perform at least 4 capillary glycaemic tests per day (SMBG) with 
a calibrated digital glucometer (Contour, Bayer, the Netherlands) for sensor calibration and 
to obtain correlation coefficients between the SMBG and the CGMS values. The first capillary 
blood glucose value was measured after 60 min of using the CGMS. Each participant noted 
glucose values, meal times, insulin doses, and special events. The CGMS did not display actual 
glucose levels, leaving the patient blind to prevailing glucose values. At the end of the study 
the sensor was removed. Sensor data were uploaded to the Medtronic CareLink iPro Clinical 
Application via the internet after each study night.
O b j e c t i v e  s l e e p  p a r a m e t e r s
P o l y s o m n o g r a p h y 
Sleep was visually scored for each of the 2 nights according to the guidelines of the American 
Association of Sleep Medicine (AASM) by a technician who was unaware of the study conditions.(10) 
In short, scoring of sleep stages depends on electroencephalography (EEG), eye movements, and 
submental muscle activity. To detect possible sleep disorders that might affect the study, respiratory 
movements were recorded by measurements of changes in nasal pressures, of truncal respiratory 
movements and of leg movements. Apnea was scored as a complete or near complete cessation 
of airflow for at least 10 seconds followed by an arousal and/or 3% oxygen desaturation; hypopnea 
was scored as a 50% decrease in airflow for at least 10 seconds followed by an arousal and/or 3% 
oxygen desaturation. The apnea–hypopnea index (AHI) is an index of sleep apnea severity that 
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combines apneas and hypopneas. Recordings were made using a portable polysomnography (PSG) 
recorder (Titanium; Embla Systems, Broomfield, CO). Sleep and wake stages were visually scored 
in consecutive epochs of 30 s, resulting in a list of epochs spent in wake, stages I (drowsiness), II, III 
(slow-wave sleep), and rapid eye movement (REM) dream sleep. The times at which subjects went 
to bed and turned out the lights as well as times getting out of bed were noted. 
G l y c e m i c  c o n t r o l  q u e s t i o n n a i r e
History of glucoregulation was gathered from medical records and a short survey, focusing on 
age of diagnosis, diabetes duration, insulin management, frequency of severe hypoglycaemic 
episodes and/or hyperglycaemic episodes, and mean fasting plasma glucose values. Early-onset 
of disease was defined as diagnosis before the age of five years. Severe hypoglycemia was defined 
as any event requiring the assistance of another individual, including seizure and unconsciousness, 
with either blood glucose <2.78 mmol/l and/or subsequent reversal of symptoms with oral 
carbohydrate, glucagon injection, or intravenous glucose.(11) If severe hypoglycemic episodes had 
occurred, their nature was established, i.e. their total number, and age at first episode.
S t a t i s t i c a l  a n a l y s i s
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc.,Chigago, IL). Continuous variables 
were described as mean ± SEM; categorical variables were expressed as proportions. The analysis 
comprised the comparison of the polysomnographic parameters of the patients with type 1 diabetes 
of both study days. We used the non-parametric Wilcoxon signed rank test or the Students t-test 
for differences in means for continuous variables, and the Chi-square (X2) test for differences in 
proportions for categorical variables within patients. The mean±SEM glucose values and variability 
during study nights were obtained from the Medtronic CareLink iPro Clinical Application (Medtronic 
Minimed iPRO-2, Northridge, CA, US). The level of significance was set at P < 0.05. 
R E S U L T S
P a t i e n t  c h a r a c t e r i s t i c s  ( Ta b l e  1 )
We studied 7 patients with well-controlled type 1 diabetes on stable continuous subcutaneous insulin 
infusion (CSII) (4 men, age 37.4±5.0 yr, body mass index 25.1±1.3 kg/m2, HbA
1c
 6.9±0.2% (51.4±2.2 
mmol/mol), and mean insulin infusion rate 0.7±0.0 units/kg/day). The mean disease duration was 
20.6±2.1 yr, and 1 patient (14.3%) had early-onset diabetes. Five patients (71.4%) had experienced 
2.0±0.3 severe hypoglycemic episodes per individual during their disease duration. The mean age 
at first episode was 30.6±7.4 yr. None of the patients had micro- or macrovascular complications, 
except for one patient who was diagnosed with micro-albuminuria and used an ACE-inhibitor. 
E f f e c t s  o f  c o n t r o l l e d  h y p e r g l y c e m i a  o n  p o l y s o m n o g r a p h i c 
p a r a m e t e r s  ( Ta b l e  2 ) 
Mean plasma glucose levels were 16.0±0.5 mmol/l during the hyperglycemic night, considerably 
higher than during the euglycemic night (6.5±0.6 mmol/l, P=<0.001), Figure 1. Glucose variability 
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Table 1. Clinical variables of 7 adult patients with type 1 diabetes mellitus on stable continuous subcutaneous 
insulin infusion (CSII)
Patients with type 1 diabetes (n=7)
Gender (male/female) 4/3
Age (years) 37.4±5.0 
BMI (kg/m2) 25.1±1.3
Duration of diabetes (years) 20.6±2.1
HbA1c, % (mmol/mol) 6.9±0.2% (51.4±2.2)
Mean insulin infusion rate (Units/kg/day) 0.7±0.0
Duration of CSII therapy (years) 5.6±1.4
Education level# 5.0±1.4
Use of medication, n (%) 2 (25.0)
Beta-blockers 1 (12.5)
ACE-inhibitors 1 (12.5)
a2-adrenergic agonist 1 (12.5)
Age at diabetes onset (years) 16.0±4.7
Early onset of type 1 diabetes ,n (%)* 1 (14.3)
History of SH events (n, %) 5 (71.4)
Frequency SH events** 2.0± 0.3






Hypercholesterolaemia (n, %) 0




Current cigarette smokers, n (%) none
Head injury in the past with unconsciousness none
Data are mean ± SD for continuous variables and n (%) for categorical variables; 
*Early-onset of disease is defined as onset below 5 years of age
#Education level measured with a Dutch scoring system from 1 to 8, with 1 representing unfinished primary 
school and 8 representing university at master level. 
* * Averaged amount of self-reported severe hypoglycemic events per individual. SH: severe hypoglycaemia
was significantly higher during the normoglycemic night compared to the hyperglycemic night 
(17.1±2.7% vs. 7.6±1.0%, P=0.006).
There were no significant differences in the objective sleep parameters, i.e. sleep duration, 
latency, efficiency, proportions of time spent in the sleep or wake stages, or the presence of 
sleep disturbances between the hyperglycaemic nights compared with the normoglycemic 
nights. There was also no significant effect of glucose variability on the sleep parameters. 




Table 2. The effect of hyperglycemic dysregulation versus a euglycaemic night on sleep parameters assessed by 
polysomnography (PSG) in 7 adult patients with type 1 diabetes. 
Sleep parameters hyperglycaemic night Euglycaemic night P-value
Total sleep time, TST (min) 415.0±17.7 363.7±38.0 0.165
Sleep latency (min) 13.4±2.9 22.6±6.5 0.290
Sleep efficiency (%) 85.2±3.5 81.2±5.7 0.247
Stage 1 NREM(% TST) 14.8±1.5 12.3±1.9 0.131
Stage 1 NREM (min) 72.2 ±8.1 57.4±9.0 0.102
Stage 2 NREM (% TST) 35.6±4.8 39.4±4.6 0.073
Stage 2 NREM (min) 172.8±23.0 182.9±21.7 0.358
Stage 3 NREM (% TST) 20.1±1.9 18.4±2.8 0.515
Stage 3 NREM (min) 97.6±9.0 85.1±11.8 0.258
REM (% TST) 14.8±1.8 11.2±1.3 0.142
REM (min) 72.4±9.3 52.1±6.7 0.127
Wake time (% of sleep period) 14.8±3.5 18.8±5.7 0.247
Wake time (min) 72.1±16.9 86.5±25.9 0.288
Snoring (% of TST) 2.3±2.1 7.4±4.7 0.210
No. of Limb movements 171.3±104.7 84.7±58.3 0.159
Apnea/hypopnea index (/hr) 4.0±1.8 6.4±2.1 0.221
Data are mean ± SEM. TST: Total Sleep Time 
Figure 1. Mean glucose values (mmol/l) in 7 patients with type 1 diabetes during the night of hyperglycemic 
dysregulation vs. euglycemia. Data are mean ±SEM
D I S C U S S I O N
The aim of the present study was to assess the impact of hyperglycemic dysregulation on 
objective sleep characteristics in well-controlled patients with type 1 diabetes. This study 
demonstrates that hyperglycemic dysregulation does not have major effects on objective sleep 
characteristics in otherwise well-controlled patients with type 1 diabetes. 
This is the first study that documents the effects of short-term hyperglycemic dysregulation 
on objective sleep characteristics. Previous studies on the relation between sleep characteristics 
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and metabolic regulation focused on the impact of hypoglycemia on sleep architecture in 
patients with type 1 diabetes(12;13) or the reverse effects of impaired sleep duration on glucose 
regulation and insulin sensitivity.(5) We hypothesized that hyperglycemic dysregulation would 
affect objective sleep parameters, i.e. sleep duration, efficiency, latency, obstructive sleep 
apnea syndrome (OSAS), and composition of sleep and wake stages. However, a reduction 
of insulin infusion rates by 50% with resultant hyperglycemia did not significantly affect 
these parameters in this strictly controlled study design. Moreover, there were no significant 
differences in the number of toilet visits during both study nights, since hyperglycemia might 
have induced osmotic diuresis, which could have disturbed sleep.(14)
Intensive insulin therapy is the hallmark of treatment of type 1 diabetes. Although insulin 
analogues and insulin pumps enable more physiological insulin replacement approaches, it is 
impossible to achieve normal glucose physiology. Intra-individual variations in physiological 
factors may interfere with glucoregulation in patients with type 1 diabetes, e.g. partial sleep 
deprivation(5), dietary macronutrient composition(15;16), physical activity, and stress.(17-19) Previous 
studies showed that nutrients, such as glucose, as well as the timing of meals, can reset the 
bodily rhythms of rodents.(20) Moreover, the timing of carbohydrate rich meals affects circadian 
rhythms(21), but it is unknown whether this affects sleep patterns. Clinical interventions confirm 
cross-sectional observations that there is a relation between the intake of macronutrients 
and sleep. Carbohydrates and fats, at least in large quantities, may modulate sleep quality 
by influencing the ratio of REM and NREM sleep.(15) Therefore, we speculated that the major 
increase in glucose levels, associated with a major reduction in insulin administration in 
patients with type 1 diabetes, might also affect objective sleep characteristics. However, 
despite a considerable increase in glucose levels, we could not establish any significant effect 
on objective sleep characteristics in patients with type 1 diabetes. This real life situation is 
provides important knowledge for the care of patients with type 1 diabetes mellitus. 
C O N C L U S I O N
In conclusion, reduction of insulin availability, resulting in hyperglycemia, does not significantly 
disturb objective sleep parameters.
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A B S T R A C T
B a c k g r o u n d 
Patients with type 1 diabetes have altered sleep characteristics and are thought to have deficits in 
sustained attention. We compared the Sustained Attention to Response Task (SART) of patients 
with type 1 diabetes to that of healthy controls, and related results with sleep characteristics 
and disease- related factors . 
M e t h o d s 
The SART was applied in 122 patients and 109 controls. Glucoregulation was assessed by HbA
1c
-
values and a questionnaire assessing glycemic history. Clinical parameters were obtained from 
medical charts. Polyneuropathy was assessed by neurological examination and quantitative 
sensory testing. Sleep characteristics were assessed with sleep questionnaires. Anxiety and 
depression scores were assessed by the Hospital Anxiety and Depression Scale.
R e s u l t s
The SART reaction time (RT) was significant longer than in controls (327±5 ms vs. 285±3 ms, 
p<0.001), although there were no significant differences in error scores. Repeated measurement 
analyses showed that diabetes per se was associated with prolonged RT (P<0.001) and more 
commission errors (p=0.010). None of the sleep-related and diabetes-related factors were 
associated with these SART parameters. 
C o n c l u s i o n s
Patients with type 1 diabetes had impaired sustained attention, which was associated with 
diabetes per se, but not with disturbed sleep characteristics. 
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I N T R O D U C T I O N
Patients with type 1 diabetes perform less well on neuropsychological tests, including 
psychomotor speed, sustained attention, and speed of information processing.(1;2) Although 
various disease-variables are associated with cognitive impairment – e.g. chronic hyperglycemia(3), 
microangiopathy(4;5), age at onset(4;6) or disease duration(6), and structural brain defects(7;8) - 
the pathophysiology of cognitive dysfunction is not well understood. Studies on the effect of 
severe hypoglycemia on cognitive function are conflicting: whereas some retrospective studies 
suggested an association in adult patients(9;10), large prospective studies failed to conform this.(11;12)
Disturbed sleep could be an alternate explanation, as patients with type 1 diabetes have 
altered subjective and objective sleep characteristics compared to controls(13;14) and because 
disturbed sleep impairs cognitive functioning.(15;16) The psychomotor vigilance test (PVT)(17) and 
the Sustained Attention to Response Task (SART)(18) assessed sustained attention, are sensitive 
to sleep deprivation in healthy controls(19) or excessive sleepiness in sleep-disordered patients 
compared to controls, respectively.(20) Sleep characteristics and their relation with sustained 
attention have, however, not been studied in type 1 diabetes. 
We hypothesized that type 1 diabetes is associated with impaired sustained attention, and that 
this would be associated with sleep disturbances or disease-related factors. We therefore aimed 
the following: 1) to compare sustained attention in patients with type 1 diabetes and controls; and 
2) to assess if impaired sustained attention was associated with sleep or disease- related factors. 
M A T E R I A L  A N D  M E T h O D S
S u b j e c t s
We included 122 consecutive patients with type 1 diabetes (74 men, 43.4±1.1 yr, 24.5±0.2 kg/m2) 
from our outpatient clinic of our hospital, and 109 comparable healthy controls (57 men, 
42.7±1.3 yr, 24.5±0.3 kg/m2) through an advertisement in a local paper and through patients. 
Exclusion criteria were:1) age <18 or >65 yr; 2) alcohol or drugs abuse; 3) psychiatric disorders or 
use of psychotropic medication; 4) history of cerebrovascular accident; 5) history of epilepsy 
or use of anti-epileptic drugs; 6) other endocrine disorders, including menopausal symptoms; 
7) pregnancy or lactation; 8) chronic use of glucocorticoids or medication known to affect 
cognitive function; 9) visual impairment; 10) sleep disorders, shift work, travelling across time 
zones in the previous month, and chronic use of sleep medication; 11) polyneuropathy due to 
conditions other than diabetes; 12) pain not due to peripheral polyneuropathy. 
The following data were obtained from medical records for the year preceding the study. 
Microvascular complications included (a) retinopathy (retinal photography, ophthalmologic 
examination, previous laser therapy), (b) nephropathy (increased urinary albumin-to-creatinine 
ratio (men >2.5 μg/umol, women >3.5 μg/umol)). Macrovascular complications were coronary 
artery disease (proven by cardiac exercise test, coronary angiography, myocardial infarction 
and/or coronary artery bypass surgery or percutaneous coronary interventions), or peripheral 
vascular disease (reduced ankle-arm index or angiography). Hypertension was defined as systolic 
blood pressure >135 mmHg or diastolic blood pressure >85 mmHg at multiple occasions, or use of 
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antihypertensive agents for the treatment of hypertension. Other macrovascular risk factors –i.e. 
current smoking status, obesity and hypercholesterolaemia - were assessed by questionnaire and 
medical records. HbA1c values had been obtained within the previous 3 months. Polyneuropathy 
in the feet was assessed using the modified Toronto Clinical Neuropathy scale (mTCNs) (21) and a 
neurothesiometer (Scientific laboratory supplies LTD, Notthingham, UK). For both measures the 
abnormality threshold was defined as the upper 2.5% percentile of data from the control group. 
Peripheral polyneuropathy was considered present when mTCNs was >5 points or the vibration 
perception threshold was >18.0 V. The study was approved by the medical ethical committee of 
Leiden University Medical Center, and informed consent was obtained from all subjects. 
To evaluate any immediate effects of blood glucose levels on the SART, we measured 
glucose values just before the start of the first SART test in 10 patients with type 1 diabetes 
with a calibrated digital glucometer (Contour, Bayer, the Netherlands) and a continuous 
subcutaneous glucose sensor (iPro2, Medtronic, Northridge, CA, US). 
S u s t a i n e d  a t t e n t i o n  t o  r e s p o n s e  t a s k
SART is a go/no-go task in which the no-go target appears unpredictably and rarely.A number from 
1 to 9 was shown 225 times in white on a black computer screen in a quiet room with dimmed lights. 
Each of the nine numbers was shown 25 times in a predetermined and quasi-random order. The font 
size was chosen at random from 26, 28, 36, or 72 points. Each number was presented for 250 ms, 
followed by a black screen for 900 ms. Subjects had to respond to the appearance of each number 
by pressing a button, except when the number was 3. Subjects were instructed that accuracy and 
speed were equally important. The SART was performed two times: the time in between was spent 
on an outpatient visit for the patients, and completion of the questionnaires and foot examination 
for the controls. The total error score consists of the number of times the button was pressed when a 
‘3’ was presented (errors of commission), plus the number of times when no key was pressed when it 
should have been (errors of omission). The reaction time (RT) is the average time in ms between the 
appearance of any number and the subject’s appropriate presses.(18) The subjects were not allowed 
to drink coffee 1 hour before and between the two tests. 
S l e e p  q u e s t i o n n a i r e s
P i t t s b u r g h  S l e e p  Q u a l i t y  I n d e x 
The Pittsburgh Sleep Quality Index (PSQI ) is a 19-item questionnaire for assessing subjective 
sleep quality over the previous month. These questions generate 7 component scores, weighted 
equally from 0 to 3. Global PSQI score ranges from 0 to 21, with higher scores indicating worse 
sleep quality. PSQI scores >5 have a diagnostic sensitivity of 89.6% and a specificity of 86.5% to 
detect poor sleep quality.(22)
E p w o r t h  S l e e p i n e s s  S c a l e 
The Epworth Sleepiness Scale is an eight-item questionnaire, concerning the likelihood of 
falling asleep in common situations on a scale of 0 to 3. Scores ranges from 0 to 24. Scores >10 
are interpreted as hypersomnolence.(23)
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B e r l i n  Q u e s t i o n n a i r e
The Berlin Questionnaire cconsists of ten questions on risk factors for obstructive sleep 
apnea (OSA), subdivided into three symptom categories: 1) snoring and apneas (6 points), 
2) wake-time sleepiness or fatigue (3 points), and 3) presence of obesity or hypertension (2 
points). Two or more categories positive (category 1 and 2: two or more points, category 3: one 
or more points) are interpreted as high risk for sleep apnea.(24)
G l y c a e m i c  c o n t r o l  q u e s t i o n n a i r e
History of glucoregulation was gathered from medical records and a questionnaire focusing on 
age of diagnosis, diabetes duration, insulin management, frequency of severe hypoglycaemic 
episodes and/or hyperglycaemic episodes, and mean fasting plasma glucose values. Early-
onset of disease was defined as diagnosis before the age of 5 years. Severe hypoglycaemia 
was defined as any event requiring the assistance of another individual, including seizure 
and unconsciousness, with either blood glucose <2.78 mmol/l and/or subsequent reversal 
of symptoms with oral carbohydrate, glucagon injection, or intravenous glucose.(9) If severe 
hypoglycaemic episodes had occurred, their nature was established, i.e., their total number, 
and age at first episode. This questionnaire was mailed to the subjects afterwards, and was 
completed by 102 of 122 (83.6%) patients. 
h o s p i t a l  A n x i e t y  D e p r e s s i o n  S c a l e 
Because depression impacts on cognitive performance, the Hospital Anxiety Depression Scale 
(HADS) was used, consisting of 14 items scoring anxiety and depression. Each item is measured on a 
four-point scale. Scores for anxiety and depression subscale range from 0 to 21, and total score range 
from 0 to 42. Higher scores indicate more severe anxiety or depression. A total score higher than 13 
points on both subscales together is used to characterize subjects as anxious or depressed.(25)
S t a t i s t i c a l  a n a l y s i s
Data were analyzed using PASW Statistics version 17.0.2 (SPSS Inc.,Chigago, IL, USA). Continuous 
variables were described as mean±SE; categorical ones as proportions. We used the independent 
t-test or Mann-Whitney U-test for differences in continuous variables, and the Chi-square (X2) 
test for proportions. We used a repeated-measurement analysis to explore differences between 
the two groups across time, and group by time interactions. We considered three models that 
were adjusted as follows: model 1) Unadjusted model; model 2) as model 1 plus RT (for errors of 
omission and commission); model 3) as model 2 plus total HADS scores, age, gender, BMI and 
the individual sleep characteristics,i.e. sleep quality, sleep duration, daytime sleepiness, and 
the risk for OSA. The β coefficients and p-values of these analyses were reported. Significance 
level was Bonferroni-corrected. 
To investigate which variable, if any, affected the three parameters of the SART – i.e. RT, 
errors of omission and commission– we performed general linear model analysis for the 
following variables: diabetes duration (years), Hba
1c
, early onset of diabetes, retinopathy, 
nephropathy, peripheral polyneuropathy, macrovascular disease, hypertension, one or 
85
7
more other macrovascular risk factors- i.e. presence of smoking, and/or obesity, and/or 
hypercholesterolaemia -, and severe hypoglycaemia. The model was created from a saturated 
model including all disease related factors, followed by removing non-significant parameters as 
long as the model fit was not significantly impaired. We adjusted for age, sex, BMI, HADS scores, 
test, and RT, by including them as covariates. The β-coefficients, standard errors of the mean 
and the p-values of these analyses were reported. Significance level was Bonferroni corrected. 
Missing variables of the HADS were replaced with means of the controls or the patients. 
R E S U L T S 
S u b j e c t  c h a r a c t e r i s t i c s  ( Ta b l e  1 )
We included 122 patients with type 1 diabetes (74 men, 43.4±1.1 yr, 24.5±0.2 kg/m2, HbA
1c
 7.7±0.1% 
(61±1.3 mmol/mol)) and 109 comparable healthy controls (57 men, 42.7±1.3 yr, 24.5±0.3 kg/m2). 
Fourteen (11.5%) patients had early-onset diabetes. Sixty-three patients (64.3%) had experienced 
one or more episodes of severe hypoglycemia with a mean of 8.0 ± 1.3 episodes per individual. 
The mean age at first episode was 25.5 ± 1.5 yr (n=59). Patients scored significantly higher on 
the HADS questionnaire (7.8±0.5 vs. 5.3 ±0.3, p<0.001). Microvascular complications were 
present in 35 patients (28 patients had a diabetic retinopathy, 21 patients had nephropathy, and 
44 patients had peripheral polyneuropathy). Macrovascular complications were present in 12 
(9.8 %) patients. Forty-three patients (35.2%) had hypertension; 56 (45.9%) patients had one or 
more other macrovascular risk factors. 
S l e e p  q u e s t i o n n a i r e s  (d a t a  n o t  s h o w n )
Mean sleep duration in the PSQI did not differ between patients and controls (7.2 ± 0.1 vs. 7.1 ± 0.1 
hr, p=0.17) nor did global PSQI-scores. However, a PSQI score >5 occurred in ~ 30% of the patients 
and in 18.3% of the controls, indicating poorer sleep quality in the patient group (p=0.042). 
More patients were at risk for obstructive sleep apnea than controls (BQ, 17.1 vs. 5.5%, p=0.006). 
There were no significant differences in ESS-score (patients 5.8 ± 0.4 vs. controls 5.3±0.4, p=0.37). 
Daytime sleepiness affected 19.0% of the patients vs. 11.9% of the controls (p=0.14). 
S u s t a i n e d  a t t e n t i o n  t o  r e s p o n s e  t a s k  d a t a  ( Ta b l e  2 )
At the first SART test, error scores did not differ between groups, but the mean RT of patients 
was significantly higher than that of controls (331±6 ms vs. 294±4 ms, p=<0.001). In the second 
SART, the RT was still significantly longer in patients than in controls (323±6 ms vs. 275±4 ms, 
p=<0.001), but now patients made significantly fewer errors of commission than controls 
(8.1±0.5 vs. 9.7±0.5, p=0.005), when compared unadjusted. 
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Table 1. Clinical variables of 122 adult patients with type 1 diabetes and 109 group-matched healthy controls.




Age (years) 43.4±1.1 42.7±1.3 0.751
Gender (n, % male) 74 (60.7) 57 (52.3) 0.200
BMI (kg/m2) 24.5±0.2 24.5±0.3 0.782
HbA1c, % (mmol/mol) 7.7±0.1 (61±1.3) NA
Insulin, n (%) NA
Continuous s.c. insulin infusion 21 (17.2) NA
Multiple insulin injections 101 (82.8)





Calcium antagonists 9 (7.4)
Angiotensin II receptor antagonist 12 (9.7)
Statins 43 (45.2)
Type 1 diabetes duration (years) 25.4±1.0 NA
Age at diabetes onset (years) 18.2±1.0
Early onset of type 1 diabetes (n, %)* 14(11.5) NA
History of severe hypoglycemic events (n, %) 63 (64.3)
Frequency severe hypoglycemic events** 8.0±1.3 NA
Age at first SH episode 25.5±1.5 NA
Hypertension (n, %) 43 (35.2) NA
Retinopathy (n, %) 28 (23.0) NA
None or background retinopathy 64 (74.4)
(Pre)-proliferative diabetic retinopathy 1 (3.5)
Not specified 4 (14.3)
Laser treatment 23 (19.5)
Nephropathy (n, %) 21 (17.2) NA
Peripheral neuropathy (n, %) 44 (38.3) 1 (1.0) <0.001
mTCNs-score 5.0±0.5 1.3±0.1 <0.001
Neurothesiometer (Volt) 11.1±0.8 6.4±0.4 <0.001
Macrovascular disease *** 12 (9.8) NA
One or more other vascular risk factors 56 (45.9) NA
HADS 
Anxiety score 4.8±0.3 3.6±0.3 0.010
Depression score 3.1±0.3 1.7±0.2 <0.001
Total score 7.8±0.5 5.3±0.3 <0.001
Score > 13 15 (14.7) 6 (6.7) 0.067
Current cigarette smokers, n (%) 18 (14.8) 12 (11.2) 0.414
Fasting glycaemia > 7 mmol/l 71 (30.7) NA
Data are mean ± SE for continuous variables and n (%) for categorical variables; 
NA, not applicable; SH, severe hypoglycaemia; HADS, Hospital Anxiety and Depression score ; mTCNs, modified 
Toronto Clinical Neuropathy scale; BMI, body mass index; ACE, angiotensin-converting-enzyme. 
*Early-onset of disease is defined as onset below 5 years of age
* * Averaged amount of self-reported severe hypoglycemic events per individual. 
***macrovascular complications without overt cerebrovascular disease. 
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Table 2. Unadjusted results of the two Sustained Attention To Response Tasks (SART) of 122 patients with type 1 
diabetes compared to 109 group- matched healthy controls.





Errors of omission/200 1.9±0.4 1.0±0.2 0.117
Errors of commission/25 8.6±0.5 8.9±0.5 0.511
Total error score/225 * 10.4±0.7 10.0±0.5 0.914
Mean RT (ms) 330.6±6.1 294.4±4.1 <0.001
SART 2
Errors of omission/200 1.3±0.4 0.8±0.2 0.097
Errors of commission/25 8.1±0.5 9.7±0.5 0.005
Total error score/225 * 9.4± 0.7 10.5±0.5 0.023
Mean RT (ms) 322.7±6.4 275.3±3.8 <0.001
Mean results **
Errors of omission 1.6±0.3 0.9±0.1 0.092
Errors of commission 8.4±0.4 9.3±0.4 0.037
Total error score* 9.9±0.6 10.2±0.5 0.199
Mean RT (ms) 326.8±5.4 284.9±3.4 <0.001
Data are mean ± SEM; 
RT, reaction time
* Total errors: sum of omission and commission errors. 
** mean of the first (SART 1) second (SART 2) SART
R e p e a t e d  m e a s u r e m e n t  a n a l y s i s  o f  t h e  c o m b i n e d  e f f e c t  o f  g r o u p  
a n d  r e p e t i t i o n  ( Ta b l e  3 )
R e a c t i o n  T i m e  ( RT ) ,  m s .
Comparison of the first and second SART test with repeated-measures analysis showed that 
diabetes per se was significantly associated with an increased RT (47.5, p <0.001), model 1. 
Model 3, including correction for possible confounders linked to the presence of diabetes, 
showed a significant association between diabetes mellitus and an increased RT (43.3, 
p<0.001). In addition, older age (1.4, p<0.001) and higher BMI (0.2, p=0.027) were associated 
with increased RT. After correction for multiple comparisons, only older age still remained 
significantly associated with RT (Data not shown). 
E r r o r s  o f  c o m m i s s i o n
There were significant differences in the rates of commission errors between the two groups. 
Diabetic patients made significantly fewer errors of commission (-0.19, p=0.015). On repeating 
the SART the controls significantly made more errors of commission in contrast to patients (0.15, 
p=0.040), model 1. When we included the RT in the analysis to control for its potential confounding 
effect on the error scores, model 2, the RT proved to have a significant negative association with 
the rate of errors of commission (p<0.001). After correction for RT patients indeed tended to 
make more errors of commission, but this was not statically significant (p=0.079). Corrected for 
the possible confounders that could possibly affect the commission errors, the diabetic patients 
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Table 3. Results of a repeated-measurement analysis to the influences of group, test and their interaction on 
SART RT and accuracy measures
Reaction time (ms)
Beta/S.E./ P 




 Model 1 Intercept:322.8/6.4/<0.001 Intercept:2.1/0.06/<0.001 Intercept:0.28/0.23/0.238
Group (0) 47.5/7.4/<0.001 -0.19/0.8/0.015 0.6/0.2/0.019
Test (0) 7.8/6.3/0.214 0.06/0.05/0.266 0.4/0.2/0.092
GroupxTest (0x0) 11.3/7.3/0.123 -0.15/0.07/0.040 N.I.
Model 2 N.A. Intercept:4.5/0.1/<0.001 Intercept:0.28/0.23/0.238
Group (0) 0.10/0.6/0.079 0.6/0.2/0.019
Test (0) 0.13/0.4/<0.001 0.4/0.2/0.092
GroupxTest (0x0) 0.1/0.05/0.133 NI
Model 3 Intercept:285.3/60.8/<0.001 Intercept:3.8/0.3/<0.001 Intercept:-3.3/1.2/0.002
Group (0) 43.3/7.4/<0.001 0.12/0.04/0.010 0.5/0.3/0.081
Test (0) 7.8/6.3/0.220 0.10/0.03/<0.001 0.35/0.2/0.096
GroupxTest (0x0) 11.3/7.4/0.124 NI NI
The model was created from a saturated model including all individual variables and the possible interaction, 
followed by removing non-significant parameters as long as the model fit was not significantly impaired.
Group 0= diabetes mellitus, Group 1= controls; Test 0 = SART1, Test 1= SART 2
Model 1: Unadjusted; Model 2: adjusted for RT; Model 3) model 2, plus total HADS scores, age, gender, BMI and 
the individual sleep characteristics.
S.E., standard error of the mean; P, P-value; NI, not included, i.e. no significant contribution to the final model; 
NA, not applicable
made significantly more commission errors (p=0.010) and all subjects (patients and controls 
together) made more errors in the first test than the second test (0.10, p=0.001), model 3. 
E r r o r s  o f  o m i s s i o n
Diabetes per se was significantly associated with a higher rate of errors of omission compared to 
controls (0.6, p=0.019), model 1. After we included the possible confounders related to diabetes 
in the analysis (model 3), this association was no longer significant (p=0.081). In addition, male 
sex (0.65, p=0.006) was significantly associated with more errors of omission (not shown). 
A s s o c i a t i o n  o f  d i a b e t i c  r e l a t e d  r i s k  f a c t o r s  w i t h  S A RT  p a r a m e t e r s  
i n  p a t i e n t s  ( Ta b l e s  S 4  a n d  S 5 ) 
R e a c t i o n  T i m e  ( m s )
Analysis of possible risk factors that could affect RT in patients with type 1 diabetes showed no 
significant associations with a disease-related risk factor after multiple corrections. 
E r r o r s  o f  c o m m i s s i o n
Analyses for variables that could affect the commission errors in the patients showed significant 
associations between retinopathy (0.16, p=0.019) and early onset of disease (0.29, p=0.021). 
After multiple corrections, these associations were no longer significant. 
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E r r o r s  o f  O m i s s i o n
Repeated measurement analysis within the patients showed no significant associations 
between the errors of omission and any of the disease-related factors. 
E f f e c t  o f  g l u c o s e  c o n c e n t r a t i o n s  o n  S A RT  o u t c o m e
Data of euglycemic versus hyperglycemic test in 10 type 1 diabetes patients showed that that 
the individual parameters of sustained attention measured with the SART test were not different 
between the euglycemic (6.8 ±0.6) and hyperglycaemic conditions (18.8±0.7). 
D I S C U S S I O N
This study shows that type 1 diabetes per se is associated with impaired sustained attention, 
indicated by a significantly increased RT. These patients also made fewer commission errors, 
but previous studies showed that the number of commission errors was inversely correlated 
with RT.(17;26-28) After correction for the RT, patients actually made more errors of commission. 
This could implicate that impaired accuracy in part was ‘masked’ by their increased RT. After 
correction of important confounders, more frequently found in diabetic patients, the RT and 
commission errors still remained significantly higher in patients. There was no relation between 
RT and impaired sleep characteristics or disease- related variables. 
S u s t a i n e d  a t t e n t i o n  i n  p a t i e n t s  w i t h  t y p e  1  d i a b e t e s
Deficits in sustained attention have been reported in previous studies of type 1 diabetes(29-31), 
concerning a study in children(29), assessing the effect of acute hypo- or hyperglycemia(31), using 
various tests.(29-31) The current study extends those observations in several aspects: (a) sustained 
attention was impaired in a large carefully characterized group of consecutive adult patients, 
after exclusion for most variables that could affect cognitive function; (b) we used the SART, 
an easily administrated tool allowing quick measurement of sustained attention, taking into 
account RT and accuracy, both important for everyday functioning; (c) and most importantly, 
we aimed to explore all possible risk factors for impaired sustained attention in the patients, 
including impaired sleep characteristics, frequently seen in these patients(14) and associated 
with impaired sustained attention.(15;16;32)
The main finding of our study was that diabetes itself was independently associated with 
impairments in RT. The finding that mean RT was significantly longer in patients than in controls 
is in accordance with previous literature.(4;5;31;33) Evidence is increasing that cognitive slowing is the 
core feature of the diabetes-associated cognitive decline , sometimes inappropriately called a 
‘central neuropathy’.(2;34) The complex multi-factorial pathophysiology of changes in the central 
nervous system in diabetic patients has not yet been fully elucidated. Different neuroradiological(35) 
and electrophysiological alterations, i.e. increased P300 latency(36), in brain were found in patients 
with type 1 diabetes, but data on the relation of imaging findings, risk factors and neurocognitive 
functions are scarce. Within the diabetic group HbA1c was significantly associated with more errors 
of commission, which could implicate more brain damage in poorly controlled diabetes. 
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There was no effect of current glycemic state on SART outcome in a small substudy, in line with 
previous studies showing minimal or no changes in cognitive function during hyperglycaemia.(29)
S l e e p  c h a r a c t e r i s t i c s  a n d  s u s t a i n e d  a t t e n t i o n
Although disturbed sleep characteristics are part of the complex syndrome of type 1 diabetes(13;14), 
and the SART has been shown to be sensitive(19;20), we did not find a relation between individual 
sleep characteristics and parameters of sustained attention in this study using subjective sleep 
questionnaires. The reasons are unclear; it is possible that the sleep disorders were not serious 
enough. We also cannot exclude that some of the missed glycemic control questionnaires 
included hypoglycemic episodes that influenced sleep. Additional studies with objective sleep 
characteristics are warranted. 
C O N C L U S I O N S
The present explorative study demonstrates impaired sustained attention in patients with type 
1 diabetes compared to healthy controls. Diabetes itself is an important risk factor for impaired 
sustained attention. However disturbed sleep characteristics were not associated with impaired 
sustained attention in our patients.
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Supplemental Table 5. Analysis of disease related factors determining errors of commission and omission 
within patients with type 1 diabetes
Potential factors Errors of commission Errors of omission
Basis (B/SE/P-value) 4.0/0.40/ <0.001 1.52/1.8/0.400
Disease- related variables
Diabetes duration ,years NI  0.02/0.02/0.348
HbA1c, % 0.04/0.03/0.172  0.04/0.14/0.795
Early onset of disease, <5 years 0.29/0.12/0.021 -0.58/0.6/0.314
SH-events in the past 0.07/0.08/0.387 0.21/0.3/0.452
Presence of retinopathy 0.16/0.07/0.019 NI
Presence of nephropathy -0.2/0.09/0.076 NI
Presence of peripheral neuropathy -0.05/0.07/0.469 0.64/0.4/0.086
Presence of macrovascular disease*  NI NI
Macrovascular risk factors, n (%)
Hypertension NI  -0.69/0.6/0.249
Other # 0.14/0.08/0.080  0.50/0.4/0.203
Data shown are the standardized B of independent variables predictive for the errors of commission and omission. 
NI: not included, i.e. no significant contribution to the final model
SH: severe hypoglycaemia; B:beta; SE: Standard error of the mean 
* Patients with cerebrovascular events were excluded, only patients with cardiovascular and peripheral vascular 
disease were included in the analyses. 
# defined as current smoker and/or presence of dyslipidaemia and/or obesity.
Model was created from a saturated model including all disease related factors, age, sex BMI, HADS scores, Test (0/1) 
and RT followed by removing non-significant parameters as long as the model fit was not significantly impaired.
Supplemental Table 4. Analysis of possible disease related risk factors determining reaction time (RT) in 
patients with type 1 diabetes
Potential factors Reaction time (ms)
Basis (B/SE/P-value) 294.2/76.2/<0.001
Disease related variables
Diabetes duration, years 1.1/0.8/0.168
HbA1c,% -6.6/5.2/0.205
Early-onset of disease, <5 years -0.7/19.1/0.969
SH-events in the past -28.7/14.6/0.050
Presence of retinopathy -10.7/15.6/0.518
Presence of nephropathy 39.9/22.7/0.078
Presence of peripheral neuropathy 23.7/14.3/ 0.097
Presence of macrovascular disease* -23.2/22.7/0.306
Macrovascular risk factors, n (%)
Hypertension -11.8/13.3/0.374
Other vascular risk factor# 1.7/13.6/ 0.897
Data shown are the standardized B of independent predictive factors for impaired RT, ms. SH: severe 
hypoglycaemia; B:beta; SE: Standard error of the mean
. * Patients with cerebrovascular events were excluded, only patients with cardiovascular and peripheral vascular 
disease were included in the analyses. 
# defined as current smoker and/or presence of dyslipidaemia and/or obesity.
Model was created from a saturated model including all disease-related factors, Test (0/1), age, sex, BMI, and HADS 
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I .  I N T R O D U C T I O N
Intensive insulin therapy and frequent self-monitoring of blood glucose values (SMBG) are the main 
strategies for optimal replacement of endogenous insulin secretion and to attain normoglycemia 
in patients with T1DM.(1) Unfortunately, despite more physiological insulin replacement approaches 
and intensive treatment strategies, relatively few patients reach the glycemic and HbA
1c
 targets(2), 
and in general large intra-individual variations in blood glucose persist. 
Previous studies showed an important role for sleep as another physiological determinant of 
intra-individual variations in glucose metabolism in healthy controls.(3-7) The impact of impaired 
sleep characteristics on glucose regulation had not been studied in patients with T1DM prior to 
the studies described in this thesis. We hypothesized that altered sleep characteristics might 
be one of the physiological factors contributing to impaired glucose regulation in patients 
with T1DM. In addition, we hypothesized that hyperglycemic dysregulation could impair sleep 
characteristics, which, in turn, could create a vicious circle by disturbing glucose metabolism.
In the present thesis we explored the interaction between sleep characteristics and glucose 
regulation in adult patients with T1DM and healthy controls. In addition, we assessed the impact 
of impaired sleep characteristics on sustained attention in patients with T1DM. 
The major conclusions and implications of these studies are discussed in this chapter.
I I .  S L E E P  A N D  G L U C O R E G U L A T I O N 
1 .  E f f e c t  o f  s l e e p  c h a r a c t e r i s t i c s  o n  g l u c o s e  r e g u l a t i o n 
a .  S l e e p  r e s t r i c t i o n 
H e a l t h y  s u b j e c t s : 
Previous studies showed a negative impact of (partial) sleep restriction during multiple nights 
on glucose tolerance in healthy controls.(3-5) These studies were in some aspects limited as 
they did not assess insulin sensitivity by the euglycemic hyperinsulinemic clamp method, the 
gold standard for measurement of insulin sensitivity. In Chapter 2 we aimed to compare the 
impact of one single night of reduced sleep duration (4 hr) with that of a night of normal sleep 
duration (8.5 hr) on insulin sensitivity in healthy controls. We assessed insulin sensitivity with 
the hyperinsulinemic euglycemic clamp technique using stable isotopes. The results of that 
study indicate that even a single night of partial sleep deprivation reduces insulin sensitivity by 
19-25% in multiple metabolic pathways in healthy controls. In addition, our data also indicate 
that insulin sensitivity is not static in healthy controls, and can be modulated by sleep duration. 
This has also been observed to hold for other environmental factors, including exercise, and 
dietary macronutrient composition and –content.(8-10)
C l i n i c a l  i m p l i c a t i o n s :
Sleep duration has been shortened considerably in Western societies during the past decades, 
together with a simultaneously increase in the prevalence of insulin resistance and T2DM. 
Our study confirmed that shortened sleep duration is another physiological determinant that 
contributes to insulin resistance and consequently to diabetes risk in healthy controls. Sleep 
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restriction, even of a single night, can induce such effects, indicating that they are most likely 
present on a daily basis in many people. Strategies to increase sleep duration might be considered 
as a potential intervention to prevent or delay the development of T2DM in high-risk populations
P a t i e n t s  w i t h  t y p e  1  d i a b e t e s  m e l l i t u s : 
In most patients with T1DM glucose regulation cannot be completely normalized, despite 
intensive insulin treatment and large intra-individual variations in blood glucose levels persist. 
Subtle intra-individual variations in glucose regulation depend on variations in physiological 
determinants, such as dietary factors, stress and exercise.(11-13) In Chapter 3 we aimed to 
explore whether sleep restriction was another physiological determinant of impaired glucose 
regulation in patients with T1DM. We evaluated the effects of a single night of partial sleep 
restriction(4 hr) with those of a night of normal sleep duration (8.5 hr) on insulin sensitivity in 
patients with T1DM. Our results showed that one night of partial sleep deprivation reduced 
insulin-mediated peripheral glucose uptake by 14-21%. The studies in Chapter 2 and Chapter 3 
did not address the potential pathophysiological mechanisms involved in the negative effects 
of reduced sleep duration on insulin sensitivity. We speculate that these mechanisms involve 
alterations in the activity of the autonomous nervous system, in additions to the endocrine 
effects of shortened sleep duration.
C l i n i c a l  i m p l i c a t i o n s : 
This was the first study to assess the adverse effect of sleep restriction on insulin sensitivity 
in patients with T1DM. This study stresses that shortened sleep duration, even during only a 
single night, is another physiological determinant of insulin sensitivity in patients with T1DM 
and might become another therapeutic target to optimize glucoregulation in patients with 
T1DM. Endocrinologists perhaps ought to start explaining to their patients that not getting 
enough sleep may impair their insulin sensitivity, since it can be expected that sleep restriction 
increases postprandial glucose levels in the absence of concurrent adaptations of exogenous 
insulin dose. Further research of the underlying pathophysiologic mechanisms responsible for 
the effect of short sleep duration on insulin sensitivity in patients with T1DM is warranted.
b .  S l e e p  c o m p o s i t i o n
In addition to sleep duration, sleep composition is a determinant of glucose metabolism in 
healthy controls.(14) The clear ‘restorative’ role of slow-wave-sleep (SWS) in the maintenance 
of glucose metabolism has been described before.(15-17) The initiation of SWS coincides with 
neurophysiological, hormonal, and metabolic alterations, which can affect glucose regulation.(14) 
Tasali et al.(14) assessed the effect of multiple subsequent nights of SWS suppression on glucose 
tolerance, and documented that this intervention decreased glucose tolerance. However, these 
authors did not include the assessment of insulin sensitivity by the euglycemic hyperinsulinemic 
clamp method. The impact of one single night of selective on glucose regulation had not been 
studied in patients with T1DM previously. Chapter 4 described the effects of a single night of 
SWS suppression compared to a night of normal sleep on insulin sensitivity in healthy controls. 
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We used acoustic stimuli of varying frequency and intensity to suppress the SWS. Our study 
showed that a single night of selective suppression of SWS, without a change in total sleep 
duration, did not affect insulin sensitivity in healthy controls. 
C l i n i c a l  i m p l i c a t i o n s : 
Although we showed a negative impact of shortened sleep duration on insulin sensitivity 
in healthy controls and patients with T1DM in Chapter 2 and Chapter 3, respectively, there 
was no effect of a single night of suppression of SWS during maintained sleep duration on 
insulin sensitivity in healthy controls. Therefore, sleep duration rather than sleep quality, is an 
important determinant of insulin sensitivity in healthy controls. 
2 .  S l e e p  i n  p a t i e n t s  w i t h  T 1 D M
Patients with T2DM report sleep disturbances more frequently than the general population 
does.(18;19) This is relevant for glucose regulation, since previous publications have shown that 
reduced sleep duration and/or decreased sleep quality markedly reduce glucose tolerance 
and insulin sensitivity in healthy controls and patients with type 1 diabetes.(3-5;7;14;20;21) Sleep 
characteristics, and their relation with glucoregulation, have not been studied in a large cohort 
of well-characterized adult patients with T1DM. In Chapter 5 we describe a cross-sectional study 
in which we compared subjective sleep characteristics between a well-characterized large 
cohort of adult patients with T1DM and individually age, sex and BMI matched healthy controls. 
In addition, we related these sleep characteristics to glycemic control, i.e. HbA
1c
- values, and 
assessed possible risk factors for impaired sleep. We used validated sleep questionnaires to 
assess different features of sleep. We reported significant disturbed sleep quality and a higher 
risk for obstructive sleep apnea (OSA) compared with matched healthy controls. Several aspects 
influenced the outcome parameters: the HADS depression score, presence of polyneuropathy, 
habitual snoring, and other sleep disturbances were independently associated with poor 
sleep quality. We found no significant association between individual sleep characteristics and 
impaired glucoregulation. 
C l i n i c a l  i m p l i c a t i o n s : 
This explorative, cross-sectional, study is important, since disturbed subjective sleep 
characteristics are apparently part of the complex syndrome of long-standing T1DM. Although 
the presumed relationship between sleep characteristics and impaired glucose metabolism, 
assessed by HbA
1c
 values, was not observed in this study using questionnaires, additional studies 
with objective sleep measurements to assess the impact of impaired sleep characteristics on 
insulin sensitivity in patients with T1DM are described in Chapter 2-4. 
3 .  E f f e c t  o f  m e t a b o l i c  d y s r e g u l a t i o n  o n  s l e e p 
Various aspects of diabetes could be linked to disturbed sleep characteristics in patients with 
T1DM, including complications of T1DM, psychological factors and high prevalence of sleep 
disturbances (see Chapter 5). 
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In Chapter 6, we aimed to investigate the effect of controlled metabolic dysregulation, 
frequently found in patients with T1DM, on sleep characteristics in well-controlled patients 
with T1DM on stable CSII. Hyperglycemic dysregulation was induced and maintained during the 
hyperglycemic night by 50% reduction of the basal and bolus insulin infusions compared with 
the euglycemic night. The results showed that hyperglycemia induced by reduction of insulin 
infusion did not affect objective sleep parameters. Therefore, a single night of hyperglycemic 
dysregulation does not constitute an important determinant of disturbed sleep duration and 
sleep quality in T1DM patients. 
C l i n i c a l  i m p l i c a t i o n s :
Although we showed that sleep duration is a determinant of glucose regulation in both healthy 
controls and T1DM patients in Chapter 2 and 3, hyperglycemic dysregulation did not turn out to 
be a determinant of impaired sleep in patients with T1DM. Since even well-controlled patients 
experience large daily fluctuations in glucose values, these fluctuations do not explain the 
potential disturbed sleep characteristics found in the patients. 
Further objective research is warranted to elucidate the underlying mechanisms of the 
impaired sleep characteristics in patients with T1DM, since impaired sleep characteristics could 
impair glucoregulation in these patients.
I V .  S L E E P  A N D  S U S T A I N E D  A T T E N T I O N
Patients with T1DM perform less well on different neuropsychological tests, including sustained 
attention.(22;23) Although different disease-related variables are associated with cognitive 
impairment(24-29), the exact pathophysiology is not completely elucidated. The role of impaired 
sleep characteristics on sustained attention has been documented in healthy controls and 
patients with sleep disorders. The Sustained Attention to Response Task (SART)(32) has been 
proven to be sensitive to sleep deprivation in healthy controls and to excessive sleepiness in 
sleep-disorders.(30;31) However, sleep characteristics and their relation with sustained attention 
had not been studied previously in patients with T1DM. 
In Chapter 7 we describe a cross-sectional study exploring the relation between subjective 
sleep characteristics, assessed by validated sleep questionnaires, and sustained attention in 
patients with T1DM and healthy controls. We used the SART to assess sustained attention. 
The results of this explorative study indicate the presence of impaired sustained attention in 
patients with T1DM compared to healthy controls. In addition, the presence of T1DM per se 
was an risk factor for impaired sustained attention. However, disturbed sleep characteristics 
were not associated with impaired sustained attention in our patients. Additional studies with 
objective sleep characteristics are warranted. 
C l i n i c a l  i m p l i c a t i o n s :
The results of this cross-sectional study are relevant, since even mild forms of cognitive 
dysfunction, as observed in our study, might influence everyday activities. 
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V .  S U M M A R Y  A N D  C O N C L U D I N G  R E M A R k S
The present thesis described the interaction between impaired sleep characteristics and 
glucose regulation in adult patients with T1DM and healthy controls. In addition, we described 
the impact of impaired sleep characteristics on sustained attention in patients with T1DM. 
F r o m  t h e  s t u d i e s  d e s c r i b e d  i n  t h i s  t h e s i s  w e  c a n  c o n c l u d e  t h a t :
1. A single night of partial sleep restriction decreased insulin sensitivity of multiple metabolic 
pathways in healthy controls. (Chapter 2)
2. A single night of partial sleep deprivation reduced insulin-mediated peripheral glucose 
uptake in patients with T1DM. (Chapter 3)
3. A single night of selective SWS suppression did not induce insulin resistance in healthy 
controls; reduced sleep duration rather than altered sleep composition is therefore an 
important determinant of insulin sensitivity in healthy controls. (Chapter 4)
4. Disturbed sleep characteristics are part of the complex syndrome of patients with 
longstanding T1DM. (Chapter 5)
5. There is no effect of short-term controlled hyperglycemic dysregulation on objective sleep 
characteristics in patients with T1DM. (Chapter 6)
6. Diabetes per se is independently associated with impaired sustained attention in patients 
with T1DM. (Chapter 7)
Optimizing sleep duration could be a therapeutic target to optimize glucoregulation in these 
patients, since voluntary sleep curtailment is extremely common in this 24-hr modern society. 
Although we showed that reduced sleep duration has a negative impact on glucose regulation, 
short-term controlled hyperglycemia did not affect sleep characteristics, and, therefore, no vicious 
circle between sleep characteristics and dysregulation of glucose metabolism appears to be present. 
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I N T R O D U C T I E
Type 1 Diabetes Mellitus (T1DM) is een auto-immuun ziekte waarbij de insuline-producerende 
cellen in de alvleesklier verloren gaan. Hierdoor produceert het lichaam geen insuline meer, 
wat resulteert in een absoluut insuline-tekort. Het hormoon insuline is van groot belang voor 
een goede glucosehuishouding. De glucoseconcentratie in het bloed wordt normaliter strikt 
gereguleerd doordat het lichaam balanceert tussen het aanmaken van glucose (voornamelijk 
in de lever) en het opnemen van glucose uit het bloed in perifere weefsels (voornamelijk in 
skeletspieren en vetweefsels). Insuline remt normaliter de productie van glucose door de lever 
en zorgt dat het glucose opgenomen wordt in de perifere weefsels. Tevens remt het de afbraak 
van vetzuren, welke gebruikt worden als bouwsteen voor glucose in de lever. Zonder insuline 
wordt de bloedglucose-waarde te hoog (= hyperglycemie). De mate waarin de lever en perifere 
weefsels reageren op insuline bepaalt de insuline-gevoeligheid. Intensieve behandeling met 
insuline en frequente controle van de bloedglucose waarden zijn van groot belang voor een 
optimale glucoseregulatie voor deze patiënten, omdat hoge glucosewaarden zowel micro- 
(schade aan nieren, ogen, zenuwstelsel) als macrovasculaire complicaties (schade aan hart en 
bloedvaten) kunnen veroorzaken. Ondanks vele nieuwe ontwikkelingen in insuline therapieën 
de afgelopen 25 jaar, lukt het bij veel patiënten niet om een normale glucoseregulatie te 
bereiken. Dit is vooral te zien in de hoge bloedglucosewaarden en een relatief hoog HbA
1c
, 
wat een maat is voor de gemiddelde bloedsuikerspiegel van de afgelopen 3 maanden. Ook 
zijn er veel intra-individuele variaties in de glucoseregulatie bij patiënten met T1DM. Dit wordt 
voor een deel verklaard door verschillende fysiologische factoren welke van invloed zijn op de 
glucoseregulatie, bijvoorbeeld voedsel, lichamelijke activiteit en stress. 
De afgelopen jaren heeft onderzoek bij gezonde controlepersonen aangetoond dat slaap 
een belangrijke rol speelt bij de glucoseregulatie en een risico factor is voor het ontwikkelen 
van type 2 diabetes. Omdat een korte slaapduur en slaapproblemen veelvuldig voorkomen in 
onze 24-uurs maatschappij, wilden we onderzoeken of een gestoorde slaap (zowel slaapduur als 
kwaliteit) ook een rol speelt bij de glucoseregulatie in patiënten met T1DM. Ook is er is weinig 
bekend over hoe patiënten met T1DM slapen en of zij meer slaapstoornissen hebben dan gezonde 
controlepersonen. Vervolgens werd gekeken of een gestoorde glucoseregulatie ook van invloed is 
op de slaapeigenschappen, zoals onder andere op de slaapduur, slaapopbouw en het hebben van 
slaapstoornissen, en of er zo een vicieuze cirkel aanwezig is bij patiënten met T1DM. Verder hebben wij 
gekeken of patiënten met T1DM een verminderde ‘sustained attention’ (=vasthouden van aandacht) 
hebben dan gezonde controlepersonen en of dit gerelateerd was aan de slaapeigenschappen.
Dit proefschrift beschrijft de mogelijke interactie tussen slaap-kenmerken en 
glucoseregulatie bij volwassen patiënten met T1DM en gezonde controlepersonen. hoofdstuk 
1 geeft een algemene inleiding over T1DM, slaap, de interactie tussen slaap en glucoseregulatie, 
en de relatie tussen slaap en cognitie, en met name de sustained attention (vastgehouden 
aandacht). In hoofdstuk 2-4 beschrijven we zowel het effect van een korte slaapduur als het 
effect van een verminderde slaapkwaliteit op de glucoseregulatie in patiënten met T1DM en 
gezonde controlepersonen. hoofdstuk 5 beschrijft subjectieve slaapkenmerken –met behulp 
van gevalideerde slaapvragenlijsten- in een grote groep patiënten met T1DM in vergelijking 
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met individueel overeenkomstige (op leeftijd, geslacht en body mass index (BMI)) gezonde 
controlepersonen. In hoofdstuk 6 onderzoeken we of een gestoorde glucoseregulatie de 
slaap in T1DM verstoord, en zo ja, of er een vicieuze cirkel aanwezig is met betrekking tot 
slaapkenmerken en glucoseregulatie bij deze patiënten. Daarnaast kijken we in hoofdstuk 7 
of er een verschil is tussen de ‘sustained attention’ –gemeten met de ‘Sustained Attention to 
Response Task (SART)- in patiënten met T1DM en gezonde controlepersonen. En zo ja, of deze 
gerelateerd is aan een kortere slaapduur of slechtere slaapkwaliteit in patiënten met een T1DM. 
Hieronder worden de belangrijkste bevindingen van de studies die beschreven zijn in die 
hoofdstukken samengevat. 
S L A A P  E N  G L U C O S E R E G U L A T I E
E f f e c t  v a n  s l a a p  k a r a k t e r i s t i e k e n  o p  d e  g l u c o s e r e g u l a t i e 
S l a a p d u u r
Uit eerder onderzoek blijkt dat een kortere slaapduur een ongunstig effect heeft op de 
glucoseregulatie bij gezonde controlepersonen. Deze onderzoeken hebben veelal het effect 
van meerdere nachten van een totaal slaaptekort of een kortere slaapduur onderzocht op 
de glucosetolerantie (= een test die meet hoe snel het lichaam het glucose vanuit bloed kan 
verwerken). Het effect van één enkele nacht slaaptekort op de insulinegevoeligheid is nog 
niet onderzocht bij gezonde controlepersonen. hoofdstuk 2 beschrijft het effect van 1 nacht 
met een beperkte slaapduur op de insulinegevoeligheid, gemeten met de euglycemische 
hyperinsulinemische clamp methode met stabiele isotopen, bij gezonde controlepersonen. 
De ‘euglycemische hyperinsulinemische clamp methode’ is de gouden standaard voor meting 
van de insulinegevoeligheid. We vergeleken de insulinegevoeligheid na een nacht met een 
normale slaapduur (8.5 uur slaap: 23:00-7:30 uur) met de insulinegevoeligheid na een nacht met 
korte slaap (4 uur: 1:00-5:00 uur). Deze onderzoeken laten zien dat zelfs één nacht met korte 
slaapduur zowel de gevoeligheid van de lever als de perifere weefsels voor insuline vermindert 
met 19-25%. Ons onderzoek bevestigt dat een korte slaapduur een fysiologische factor is die 
bijdraagt tot insuline-resistentie bij gezonde controle-personen. 
Het effect van een korte slaapduur op de insulinegevoeligheid was nog niet eerder 
onderzocht in patiënten met een T1DM. In hoofdstuk 3 vergeleken we het effect van 1 
nacht korte slaapduur op de insulinegevoeligheid met de insulinegevoeligheid na een 
normale nacht slapen bij patiënten met T1DM. De insulinegevoeligheid werd gemeten 
met de hyperinsulinemische euglycemische clamp procedure met stabiele isotopen. Na 
één nacht kortere slaapduur was er een significante vermindering ~20% van de perifere 
insulinegevoeligheid in T1DM. 
Deze onderzoeken bevestigen dat een kortere slaapduur een risicofactor is voor 
insulineresistentie bij zowel gezonde controlepersonen als bij patiënten met T1DM. Verder 
onderzoek is nodig om het onderliggende pathofysiologisch mechanisme waarom een kortere 
slaapduur de insulinegevoeligheid verminderd te onderzoeken. 
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S l a a p o p b o u w
Ook de slaapopbouw lijkt een rol te spelen bij de glucoseregulatie. Normale slaap bestaat uit 
‘Rapid Eye Movement (REM)’ slaap en 3 stadia van non-rapid eye movement (NREM)’’ slaap: 
stadium I, II, en III. Stadium III wordt ook wel de slow-wave slaap (SWS) (‘diepe slaap’) genoemd. 
De SWS lijkt een belangrijke rol te spelen bij de glucosehouding. Een eerder onderzoek 
liet een belangrijk effect van 3 opeenvolgende nachten met volledige onderdrukking van 
SWS zien op de glucosetolerantie met de intraveneuze glucose tolerantie test (ivGTT) bij 
gezonde controlepersonen. hoofdstuk 4 beschrijft het effect van één enkele nacht met 
selectieve onderdrukking van de SWS op de insulinegevoeligheid in vergelijking met een 
nacht van normale slaap. Selectieve onderdrukking van de SWS werd bereikt door toediening 
van geluidsprikkels via luidsprekers van verschillende frequentie en intensiteit. Indien de 
personen in SWS kwamen, werd er een stimulus gegeven zodat ze in een lichter slaapstadium 
kwamen, zonder dat ze hierbij wakker werden. De slaapduur was hetzelfde bij beide nachten. 
De insulinegevoeligheid werd gemeten met de hyperinsulinemische euglyemische clamp 
met stabiele isotopen. In dit ondezoek was er geen effect van een enkele nacht selectieve 
onderdrukking van de SWS op de insulinegevoeligheid in gezonde controle-personen in 
vergelijking met de insulinegevoeligheid na een normale nacht slaap. Hieruit kunnen we 
concluderen dat slaapduur in plaats van de slaapopbouw een fysiologische rol speelt is bij de 
glucoseregulatie in zowel gezonde controlepersonen als patiënten met een T1DM.
S l a a p k e n m e r k e n  b i j  p a t i ë n t e n  m e t  t y p e  1  d i a b e t e s 
In eerdere onderzoeken hebben wij aangetoond dat een gestoorde slaapduur van invloed is op 
de glucoseregulatie (hoofdstuk 2 en 3). Slaapkenmerken en hun relatie met glucoseregulatie 
waren nog niet goed onderzocht in een grote groep volwassen patiënten met T1DM. Twee 
kleinere onderzoeken lieten zien dat patiënten met T1DM vaker een lichtere slaap hadden. Een 
ander recente onderzoek aan 37 patiënten toonde dat het obstructieve slaap-apneu-syndroom 
(OSAS) vaker voorkwam bijna patiënten met T1DM. hoofdstuk 5 beschrijft een onderzoek bij 
een grote groep volwassen patiënten met T1DM versus gezonde controlepersonen, van hun 
slaapkenmerken- en hun relatie met de glucoseregulatie. In dit onderzoek hebben wij in ruim 100 
patiënten aangetoond dat een groot deel van de patiënten een verminderde slaapkwaliteit had en 
een hoger risico op OSAS in vergelijking met individueel gematchte gezonde controlepersonen. 
Verschillende ziekte- gerelateerde factoren bleken van invloed te zijn op deze uitkomst: de HADS 
depressiescore, het wel of niet hebben van polyneuropathie, snurken, andere slaapstoornissen. 
We vonden geen relatie tussen gestoorde slaap en gestoorde glucoseregulatie. 
E f f e c t  v a n  g e s t o o r d e  g l u c o s e r e g u l a t i e  o p  s l a a p e i g e n s c h a p p e n
In hoofdstuk 6 werd gekeken naar het effect van hoge bloedsuikers (hyperglycemie), vaak 
voorkomend bij patiënten met T1DM, op de slaapeigenschappen van goed-gereguleerde 
patiënten met T1DM met continue onderhuidse insuline-infusie (CSII) pomp. Hyperglycemische 
ontregeling werd bereikt door zowel de basale standen van de insulinepomp als de bolussen 
bij de maaltijden te halveren tijdens de hyperglycemische studiedag. Dit onderzoek toonde 
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geen effect van één enkele nacht met hyperglycemie op objectief gemeten slaapparameters 
in vergelijking met een euglycemische nacht (nacht met normale bloedsuikers). Alhoewel we 
hebben aangetoond, in hoofdstukken 2 en 3, dat de slaapduur een belangrijk effect heeft op 
de glucoseregulatie in patiënten met T1DM en gezonde controlepersonen, lijkt er andersom 
geen effect te zijn van een gestoorde glucoseregulatie op de slaapkenmerken bij patiënten 
met T1DM. Concluderend vormt hyperglycemische ontregeling geen belangrijke oorzaak van 
gestoorde slaap bij patiënten met T1DM. 
S L A A P  E N  C O G N I T I E  ( ‘ S U S T A I N E D  A T T E N T I O N ’ )
Eerdere studies hebben aangetoond dat patiënten met T1DM verschillende neuropsychologische 
testen minder goed uitvoeren dan gezonde controle-personen. Alhoewel verschillende aan de 
ziekte-gerelateerde oorzaken geassocieerd waren met de uitkomsten, is de exacte oorzaak 
(pathofysiologie) niet bekend. Eerdere studies hebben aangetoond dat ‘sustained attention’ 
(vastgehouden aandacht) beïnvloed wordt door slaaptekort en slaperigheid. De sustained 
attention en de eventuele rol van slaap hierop is nog niet eerder onderzocht in patiënten met 
een T1DM. hoofdstuk 7 beschrijft een onderzoek waarin het verschil in sustained attention, 
gemeten met de ‘Sustained Attention to Response Task (SART)’, tussen gezonde controle-
personen en patiënten met een T1DM onderzocht werd. Patiënten met diabetes hadden een 
gestoorde sustained attention in vergelijking met gezonde controles. We vonden geen relatie 
tussen slaapkenmerken en sustained attention in onze patiënten. Verder onderzoek met 
objectieve metingen van slaap zijn nodig. 
S A M E N V A T T I N G  E N  C O N C L U S I E
Dit proefschrift beschrijft de interactie tussen slaapeigenschappen en glucoseregulatie in 
volwassen patiënten met T1DM en gezonde controlepersonen. Daarnaast hebben we het effect 
van slaapkenmerken op de sustained attention (=vastgehouden aandacht) onderzocht. 
We kunnen het volgende concluderen uit de studies in dit proefschrift: 
1. Een enkele nacht met korte slaapduur vermindert zowel de gevoeligheid van de lever als 
perifere insuline-gevoeligheid in gezonde controlepersonen. (hoofdstuk 2) 
2. Een enkele nacht met korte slaapduur vermindert de insuline-gemedieerde perifere 
glucoseopname in patiënten met T1DM .(hoofdstuk 3)
3. Eén enkele nacht met veranderde slaapopbouw – door selectieve onderdrukking van de 
slow-wave slaap (diepe slaap) – heeft geen effect op de insulinegevoeligheid in gezonde 
controlepersonen en is derhalve geen belangrijke determinant van insuline-gevoeligheid 
in gezonde controlepersonen. (hoofdstuk 4)
4. Gestoorde slaapkenmerken zijn onderdeel van het complexe syndroom van patiënten met 
een lang bestaande T1DM. (hoofdstuk 5)
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5. Er is geen effect van een kortdurende hyperglycemische ontregeling op de slaapparameters 
gemeten met polysomnografie bij patiënten met T1MD. (hoofdstuk 6)
6. Patiënten met T1DM hebben een gestoorde ‘sustained attention’. (hoofdstuk 7)
Het lukt heden ten dage nog steeds niet goed genoeg om de glucoseregulatie in patiënten 
met T1DM te perfectioneren ondanks nieuwe insuline-vervangende therapieën. Het is vrijwel 
onmogelijk voor patiënten met T1DM om normale glycemische en HbA
1c 
waarden te halen en er 
zijn relatieve grote intra-individuele schommelingen in de glucosewaarden. Het optimaliseren 
van de slaapduur kan een middel zijn om de glucoseregulatie te verbeteren, omdat een korte 
slaap zeer veel voorkomt in onze moderne 24-uurs samenleving. Alhoewel we hebben laten zien 
dat een verkorte slaapduur een negatief effect heeft op de glucoseregulatie, heeft een gestoorde 
glucoseregulatie gelukkig geen effect op de slaapeigenschappen. Concluderend is er geen 
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